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A fibrinogen-fibronectin complex (γγ’pdFI-pdFN) was purified from normal human 
plasma using a sequence of cryoprecipitation, ammonium sulfate fractionation, and DEAE 
Sepharose chromatography. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) under reducing condition showed both a 1:1 stoichiometric ratio of fibrinogen (FI) to 
fibronectin (FN) as well as a stoichiometric ratio of 1:1 of γ to γ’. The γγ’pdFI-pdFN complex 
was non-covalent in nature as it was disrupted by affinity adsorption to Gelatin Sepharose where 
pdFN bound strongly and the disrupted γγ’pdFI fell through the chromatographic column. 
Surprisingly, the purified γγ’pdFI-pdFN complex was more broadly thermally stable than plasma 
FI (pdFI) preparations not containing plasma FN (pdFN) and was stable at physiologic pH, ionic 
strength and temperature.  
The complex appeared as a compact species that was distinctly larger than pdFN alone 
when analyzed by high pressure size exclusion chromatography (HPSEC). Dynamic light 
scattering (DLS) showed that the native γγ’pdFI-pdFN complex is a more compact form at low 
ionic strength but adopt and extended conformation in high salt and denaturing conditions. DLS 
also showed that FN decreased the degree of polydispersity and hydrodynamic radius of both 
and ’ FI, indicating that FN interact with both subspecies. 
The clottability of the native γγ’pdFI-pdFN complex and mixtures of FN with 
unfractionated FI and FI subspecies was evaluated by Thromboelastography (TEG) assay. The 
γγ’pdFI-pdFN complex had appreciably enhanced clotting strength than comparable mixtures of 
FI and FN. FN had not effect on the polymerization rates of fibrin clots. FN, however, showed 
greater influence on the shear strength of fibrin clots even in the absence of factor FXIII 
mediated crosslinking. The maximal amplitude and shear strength increased over the entire range 
of FN concentrations for clots made from unfractionated FI and ’FI. FN had mixed effect on 
the rigidity of clots made from FI. While high concentrations of FN enhanced the maximal 
amplitude and shear modulus, low concentrations decreased both factors. 
The fibrin clots made from γγ’pdFI-pdFN showed a biological activity of human 
fibroblast and human umbilical vein endothelial cells (HUVEC) recruitment and adhesion in 
vitro exceeding that of fibrin made from equimolar concentration of  pdFI and pdFN. 
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Chapter 1 INTRODUCTION 
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Fibrinogen 
 
Fibrinogen (FI), the main component of the hemostatic system, is transformed by 
thrombin into fibrin monomers which spontaneously polymerizes forming a clot that fills the 
wound and prevent the loss of blood. In addition to preserving the integrity of the vascular 
system, the clot also initiates the wound healing process by functioning as a provisional matrix 
for cell adhesion and migration into the injured tissue [4].  Furthermore, because it has multiple 
binding sites that can react with other proteins, FI plays important roles in many physiological 
and pathological processes including fibrinolysis, cell adhesion, inflammation, angiogenesis, 
atherogenesis, tumorigenesis, and wound healing.  
Fibrinogen is a 340 kDa glycoprotein containing two identical subunits, each is made of 
three different polypeptide chains termed Aα, Bβ, and γ [5, 6] (Figure 1.1). A series of disulfide 
bonds link fibrinogen polypeptide chains forming elongated 45 nm tri-nodular structures with 
several distinct domains. These domains are arranged into three main structural regions: a central 
E, two distal D and the αC regions. The central E nodule is formed by the N-terminal portions of 
the six polypeptide chains. The distal D nodules, formed by the C-terminal portions of the Bβ 
and γ as well as a fraction of the Aα chains, are separated from the E region by coiled-coil 
regions [7, 8]. The C-termini of the two Aα-chain, known as the αC domains, have been shown 
to extends freely into solution or associate noncovalently with the central nodule [9]. The 
properties of the fibrinogen molecule are listed in Table 1.1. 
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Figure 1.1 Schematic diagram of the structure of human fibrinogen.  The domains and 
subunits are shown. The figure is adopted from reference  [1] 
Table 1.1 Properties of fibrinogen 
Molecular weight [10] 
Subunits 
Amino acids [11] 
Synthesized by 
Plasma concentration 
Carbohydrate [12] 
Isoelectric point [13] 
Diffusion coefficient [14] 
340 kDa 
Two Aα, two Bβ, and two γ 
610 Aα, 461 Bβ, 411 γ 
Primarily hepatocytes and secondarily platelets 
2-4 mg/ml 
3% of total weight, consist of Sia, Gal, Man, and GlcNAc sugars 
5.8 
2 × 10
-7 
cm
2
 s
-1
 in ionic strength of 0.15 M and pH 7.35 
 
The Aα, Bβ, and γ polypeptide chains of human fibrinogen are encoded by three separate 
genes [15]. The three genes are closely linked as a cluster in a region of 50-kilobase on 
FPB 
FPA D-region 
E-region 
D-region 
D:D D:D 
αC 
αC 
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chromosome 4q31.3. The Aα gene is in the middle and surrounded by the Bβ gene from one side 
and the -gene on the other. The Aα and Bβ genes are produced by simple transcription events, 
whereas plasma γ gene is generated by complex transcriptional event that involve differential 
RNA splicing and polyadenylation [16, 17]. 
Human FI heterogeneity results from variant splicing, phosphorylation or glycosylation, 
and a number of genetic polymorphisms [18]. The heterogeneity occurs naturally when FI is 
partially degraded during circulation to low molecular weight species with 305 kDa and 270 kDa 
with one or two of Aα-chains partially degraded at the c-terminus, respectively [19-21]. The 
heterogeneity is also due in part to the presence of a minor variant form of the -chain, known as 
γ’. The γ’-chain accounts for about 5-15% [22, 23] of normal human plasma fibrinogen and is 
formed by the alternative processing of the primary mRNA transcript [24, 25]. Amino acid 
sequence analysis has demonstrated the replacement of 4 amino acids (AGDV) in the C-terminal 
of the γ-chain with a unique 20 amino acid sequence [26] that contains two sulfated tyrosines and 
several Asp and Glu residues. Therefore, the γ′-chain is longer, contains more anion groups, and 
has higher molecular weight than the γ-chain. It has been reported that the γ′-chain bind to the B 
subunit of factor XIII (FXIII) and serves as a carrier for FXIII in plasma [27].  
Fibrinogen has the ability to interact with numerous substances with important 
physiological consequences. For example, The C-terminal of the Aα-chain (αC domains) of 
fibrinogen has binding sites for α2-AP, plasminogen, tissue-type plasminogen activator (tPA), 
and PAI-2. Table 1.2 lists binding sites and physiological roles of some fibrinogen-protein 
interactions. 
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Table 1.2 list of some molecules that interact with fibrinogen and their physiological roles 
Ligands Binding site Function 
Fibronectin [28] 
Lipoprotein (a) [29] 
 
Thrombin [30] 
 
Plasminogen [31, 32] 
 
FXIII [27] 
 
α2-AP [33] 
 
Integrin [34] 
 
Calcium 
 
Heparin [35-37] 
 
Aα-chain  
- 
γ′-chain 
Aα-chain 
γ′-chain 
Aα-chain 
Aα-chain 
 
Bβ and γ-chains 
 
Bβ-chain 
 
Cell adhesion 
Proliferation of endothelial cells 
 
Inhibit fibrinolysis  
 
Enhance fibrinolysis 
 
Clot stabilization 
 
Fibrinolysis resistance 
 
Cellular interactions 
 
Promote polymerization 
 
Cell-matrix interactions 
 
During coagulation, thrombin converts soluble fibrinogen into fibrin monomers, which 
then polymerize to form a network of fibrin fibers. This network is stabilized by thrombin 
activated FXIII to form an insoluble fibrin clot. Formation of fibrin begins when thrombin binds 
to a substrate site in fibrinogen and cleaves fibrinopeptides A (FpA) and B (FpB) from the amino 
termini of the Aα and Bβ chains, respectively. The removal of FpA exposes the polymerization 
site “A” that contains the N-terminal sequence Gly-Pro-Arg-Val of the Aα-chain, while the 
removal of FpB exposes the polymerization site “B” that contains the N-terminal sequence Gly-
His-Arg-Pro of the Bβ-chain [38]. The polymerization site “A” interacts with the complementary 
binding site of the γ-chain, whereas the polymerization site “B” interacts with the 
complementary binding site of the β chain. These interactions lead to the formation of half-
staggered, double-stranded protofibrils that undergo lateral aggregation to form fibrils [39-42]. 
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The resulting fibrils also undergo lateral aggregation forming three-dimensional fiber matrix [43, 
44]. Thrombin simultaneously converts FXIII to the active form (FXIIIa) which catalyzes the 
formation of covalent ε-(γ-glutamyl) lysine bonds between adjacent fibrin molecules. The cross-
linking occurs rapidly between Lys-406 of one γ-chain and Gln-398 of another γ-chain to form γ-
dimers [45-47]. FXIIIa also catalyzes the formation of slowly developing ε-(γ-glutamyl) lysine 
linkages between amine donor and lysine acceptor in the α-chains [48, 49] resulting in oligomers 
and larger polymers [50-52]. In addition, ε-(γ-glutamyl) lysine bonds also occur between α and γ 
chains [43, 53] as well as γ and γ chains leading to formation of hetero-dimers cross-linked α-γ 
[54], γ trimmers, and γ tetramers [43, 51, 53, 55].  
Purification of fibrinogen from human plasma 
 
Different techniques have been developed for the purification of fibrinogen from plasma 
materials. Cryoprecipitation is the most common method for isolating fibrinogen, which reduces 
the solubility of fibrinogen at lower temperature to prevent its denaturation. Compared to fresh 
frozen plasma, cryoprecipitate contains an increased percentage of fibrinogen. Cryoprecipitation 
involves freezing the citrated plasma at lower temperature, usually -20 °C or less for at least 12 
hours. The frozen plasma is slowly thawed at 4 °C followed by centrifugation to isolate the 
fibrinogen precipitate. The concentration of fibrinogen produced by cryoprecipitation is between 
8 to 30 mg/ml and can be increased to 40 to 60 mg/ml using repeated freeze/thaw cycles. An 
ultrafiltration procedure has been used to purify fibrinogen where platelet rich plasma is 
separated using an ultrafiltration chamber with a molecular weight cutoff of 30 kDa. Fibrinogen 
obtained using this method has a final concentration of 6 mg/ml and lower clottability due to 
large amount of fibrinogen being denatured. Fibrinogen has also been isolated from human 
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plasma by using chemical precipitation methods in which chemical agents such as ethanol, 
glycine, β-alanine, ether, or ammonium sulfate are used to precipitate fibrinogen from plasma. 
The clinical use of fibrinogen from pooled human plasma has been previously associated 
with a high risk of transmission of plasma–borne infectious species such as HIV, HBV, and 
HCV. The improvements in viral testing and screening have reduced, but not eliminated this risk. 
Therefore, different techniques have been developed in order to inactivate pathogenic viruses in 
fibrinogen derived from human plasma. Dry heat treatment at 60-68 °C of plasma cryoprecipitate 
inactivates HIV but it does not prevent the transmission of HCV. Plasma pathogens have been 
inactivated by treating fresh plasma with methylene blue followed by exposure to visible light. 
This approach is less effective versus non-enveloped viruses and results in approximately 20% 
fibrinogen loss. Solvent detergent treatment is the most effective procedure for inactivating 
blood-borne lipid-enveloped viruses. Solvent detergent treatment inactivates viruses by 
dissolving their lipid envelope but it does not inactivate non-lipid enveloped viruses such as 
parvovirus or hepatitis A virus.  The treatment of cryoprecipitate with a combination of organic 
solvent, tri (n-butyl) phosphate (TNBP), and detergent (sodium cholate, Tween 80, or Triton X-
100) has been shown to inactivate very large quantities of HBV, HCV, and HIV while preserving 
the activity of the purified protein. Radosevich et al showed that treating cryoprecipitate with a 
mixture of 0.3% TNBP and 1% tween 80 at 25 °C for 6 hours inactivated ≥ 5.5 log10 of HIV, ≥ 
5 log10 of VSV virus, and ≥ 6.5 log10 of sindbis virus [56]. Horowitz and coworkers revealed 
that subjecting pooled plasma to a mixture of 1% TNPB and 1% Triton X-100 for 4 hours at 30 
°C inactivates ≥ 106 CID50 of HBV, 
 
10
5
 CID50 of HCV, and 10
6.2
 TCID50 of HIV. 
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Fibronectin 
 
Fibronectin (FN) is a large, multifunctional, adhesive glycoprotein that is present in a 
soluble form in plasma or as insoluble filaments deposited on the extracellular matrix (ECM) 
[57]. It regulates cellular processes and deposited by cells into a provisional ECM where it 
functions as a scaffold to maintain and direct tissue organization [58]. FN incorporated into 
fibrin by FXIIII mediates interaction of fibrin with cells or platelets during clot formation. Bound 
fibronectin forms a three-dimensional matrix at the wound site that attracts different cell types 
and ECM proteins. 
FN is secreted as a dimer composed of two nearly identical polypeptides chains each with 
a molecular weight of ~220-250 kDa [59-61] that are linked together by two disulfide bonds 
located close to the C-terminal region [62, 63]. Each polypeptide chain is made of three types of 
repeating modular consensus amino acid sequences known as types I, II, and III (F1, F2, and F3) 
[64].  FN properties are listed in Table 1.3. There are 12 type I modules, two type II modules, 
and 15-17 type III modules, which together accounts for ~90% of the fibronectin sequence. Type 
I modules contain ~45 amino acids held together by two disulfide bonds and located in the amino 
and carboxyl termini regions of each subunit. Type II modules are composed of ~60 amino acids 
linked by two disulfide bonds and localized in the gelatin binding domain of the subunit. Type 
III modules consists of ~90 amino acids that are clustered together in the middle of the subunit 
and does not contain disulfide bonds. The N-terminal region of fibronectin consist of five type I 
modules whereas the C-terminal contains three type I modules. These modules are organized into 
well-defined functional domains that include the 70 kDa N-terminal domain, the 120 kDa central 
binding domain, and the heparin binding domain. Fibronectin domains are shown in Figure 1.2. 
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These domains interact with a variety of molecules that include other ECM components and cell-
surface receptors [65].  
Table 1.3 Properties of fibronectin 
Molecular weight 
Subunits 
Carbohydrate content [66, 67] 
Concentration in normal plasma [68, 69] 
Concentration in serum [70, 71] 
Isoelectric point 
No of cysteine residues 
Hydrodynamic properties S20,w
 
Synthesized by [72] 
Half-life [73] 
440-450 kDa 
Two subunits of 200 and 220 kDa 
~5% oligosaccharides  
300-400 µg/ml 
3 µg FN/3×10
8
 platelets in 1 ml of blood 
5.5-6.2 
1.6 free cysteine/220 kDa subunit 
12-14 S 
Hepatocytes is the major source of pdFN  
24-72 hours 
 
Plasma fibronectin (pdFN), also known as cold insoluble globulin, is synthesized by 
hepatocytes and secreted into plasma where it circulates at a concentration of approximately 300-
400 µg/ml [68, 69]. Soluble pdFN is present as a semi compact structure that is stabilized by 
intramolecular ionic interactions between specific modules that include the 1F1–5F1, the 2F3–
3F3, and 12F3–14F3 segments. Electron microscopy of pdFN deposited on surface revealed an 
extended V-shaped structure  [74-76] or compact globular molecules with dimensions varying 
from 16 × 9 nm to 51 × 32 nm [77-79]. The V region contains the binding site for α4β1 and is 
essential for the secretion of FN dimer. 
10 
 
 
  
SH 
Cellular fibronectin (cFN) is secreted by different resident cells in tissues including 
fibroblasts, osteoblasts, endothelial cells, chondrocytes, macrophages, and certain epithelial cells 
[58]. In the ECM, cFN exists in a more extended conformation forming multimeric fibrous 
strands. Many cFN subunits contain the V region but only one pdFN dimer subunit contains that 
region. 
 
 
 
 
 
 
 
 
Figure 1.2 Schematic representation of the structure of human fibronectin.  The structure 
and location of domains and subunits is shown. Fibronectin is composed of two subunits (A and 
B) that are linked by disulfide bridges at their C-terminal region. The binding sites are illustrated. 
The location of functional domains derived from partial proteolytic fragmentation of fibronectin. 
The diagram is reproduced from a previous model structure developed by Gene [2] 
Fibronectin, the second most abundant protein within the ECM, interacts with other ECM 
components and integrin receptors on the cell surface [80-82]. FN contains binding sites for 
different molecules that are localized along the length of the monomer enabling FN to play an 
important role in many physiological processes (Table 1.4). For example, FN plays a critical role 
in regulating cellular adhesion, spreading, migration, growth, proliferation, and differentiation 
29 
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[66, 83-85]. These processes are mediated through interactions of FN with a variety of ECM and 
cellular receptors, primarily of the integrin family. Integrins represent a family of dimeric cell 
surface receptors that recognize specific ECM and cell bound ligands. The cell-binding domain 
and the alternatively spliced V region are the two main sites in fibronectin that mediate cell 
adhesion. Integrins α3β1, α5β1, α8β1, αvβ1, αIIbβ3, αvβ3, αvβ5, and αvβ6 interact with the Arg-
Gly-Asp sequence in the central cell-binding domain, whereas integrins α4β1 and α4β7 interact 
with the peptide Leu-Asp-Val in the V region. These cellular functions in turn play significant 
roles in a variety of biological processes such as wound healing, homeostasis, embryonic 
development, and ECM assembly [66, 84, 86].  
Table 1.4 molecules that interact with FN and their physiological functions 
Substrate                          Function 
Fibrinogen, Fibrin [87, 88]  Hemostasis and thrombosis 
Heparin [64]    Enhance binding of FN to collagen, stabilize FN-collagen  
                                                     Complex [89] 
Hyaluronic acid [90]                         Affects interaction of hyaluronic acid with cells and ECM  
     Molecules [90-92] 
Bacteria [93, 94]   Phagocytosis 
FXIII [87, 88]   Hemostasis and thrombosis 
Cells     Promote adhesion, migration, proliferation 
Proteoglycans   Platelets aggregation [95, 96] 
DNA [97] 
Actin [98]                                      Promote phagocytosis 
Thrombospondin [99] 
Collagen [88]                                 Mediate cells binding [100, 101]                        
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FN is encoded by a single gene that is alternatively spliced at three different regions 
forming the different forms of fibronectin [102]. The alternatively spliced domains include type 
III A domain (EIIIA), type III B domain (EIIIB), and type III connecting segment (IIICS) 
domain. Exons EIIIA and EIIIB are independently excluded in most adult tissues and included 
during tissue rearrangements processes such as embryogenesis and wound healing. Domain 
IIICS contain about five distinct spliced variant and undergoes complex splicing of mRNA 
transcribed from a single exon. Domains EIIIA and EIIIB are found in a proportion in cFN 
subunits but not in pdFN, whereas domain IIICS is present in the majority of cFN subunits and 
one subunit of each pdFN dimer. While IIICS domain is essential for the secretion of FN dimer 
and provides the binding site for α4β1, domains EIIIA and EIIIB functional roles have been 
difficult to determine.  
The conformation of pdFN is affected readily by the solution and surface conditions such 
as pH and ionic environment. Studies using sedimentation velocity show that FN can undertake 
reversible transition forming a compact to a more extended form [59, 76, 103]. At lower ionic 
strength, physiological pH and salt concentration, pdFN is present in a compact structure. The 
compact form is stabilized by salt bridges between acidic and basic residues [104]. However, 
exposing pdFN to extreme pH or high salt concentration induce a reversible expansion of the 
pdFN forming an extended structure. The compact conformation of FN contains a number of 
cryptic sites which suppresses its biological activity. However, studies have shown that 
conformational changes of compact FN expose these cryptic binding sites and enable the protein 
to play important biological roles. 
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Interaction of fibronectin with fibrinogen and fibrin 
 
The reaction of fibrinogen with fibronectin has been proposed to occur through a tow step 
mechanism. The first step is a noncovalent interaction in which fibronectin binds reversibly to 
fibrinogen. In the second step, FXIIIa stabilize the noncovalent interaction by mediating the 
covalent cross-linking between the two proteins. FXIIIa catalyzes the formation of an isopeptide 
bond between ε-NH2 groups of lysine residue on one protein and γ-carbamoyl groups of specific 
glutamine residues on the other protein [105]. Studies have shown that the FXIIIa catalyzed 
fibrin-fibronectin covalent cross-linking occurs specifically between the lysyl residues in fibrin 
and glutaminyl residues in fibronectin. Figure 1.3 depicts the noncovalent and covalent 
interactions between the αC domain of fibrin/fibrinogen and NH2-terminal Fib-1 region of 
fibronectin. 
Enzymatic degradation of FN followed by affinity chromatography and amino acid 
sequencing of eluted fragments have allowed the identification of different FI binding sites in 
FN. Using this approach, each fibronectin subunit was shown to contains two fibrin binding 
regions known as Fib-1 and Fib-2. Fib-1 binding region consists of the 29 kDa N-terminal 
fragments formed by the first five finger modules of fibronectin (F1-F5) while Fib-2 region 
contains the 19 kDa C-terminal formed by the three finger modules of fibronectin (F10-F12) 
[106, 107]. Matsuka and colleagues have shown that FN fragments including the 29 kDa Fib-1 
fragment, the 19 kDa Fib-2 fragment, and the 42 kDa gelatin-binding fragment all bound to 
fibrin-Sepharose at 4 ̊C [108]. However, only the Fib-1 and Fib-2 binding fragments exhibited 
binding when temperature was raised to physiological level. By studying the binding of 
individual recombinant fingers (rF1-rF5) to fibrin-Sepharose, the same group have further 
localized fibrin recognition site within fingers 4 and 5. 
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In a separate investigation, Seidl and Hormann isolated two fibrin recognition sites from 
a chymotryptic digest of pdFN followed by fractionation on fibrin-Sepharose [106].  The first 
fragment has a molecular weight of 30 kDa and correlate to the well-established N-terminal Fib-
1 binding domain.  The second fragment with a molecular weight of 60 kDa also exhibited 
affinity towards denatured collagen and can further be degraded with cathepsin D to 18 kDa and 
40 kDa fragments. The idea of a fibrin binding site within the gelatin binding domain was 
suggested by earlier studies that showed gelatin inhibits the binding of fibronectin to a fibrin clot 
[109]. These studies also showed that the gelatin binding domain is located in close proximity to 
fibrin binding domain. The presence of the gelatin and fibrin binding domains in close proximity 
may leads to the steric interference of the two domains and help explains the affinity of 60 kDa 
gelatin domains towards fibrin [106]. 
Studies were also carried out to localize FN binding sites in FI. Using ELISA and Surface 
Plasmon resonance, Medved and colleagues studied the interaction of recombinant αC-domain of 
FI with FN [3]. They found that the amino terminal half of FI αC-domain contains FN binding 
sites and is the only region in FI that interacts with FN.  The fibrin C-terminal portion of the Aα-
chain appears to be the major recognition site for FN. This peptide is highly susceptible to 
proteolysis [110] indicating the rapid release of FN form the clot during plasmin degradation. 
The same recognition site is implicated to play a key role in the cryoprecipitation of FN and FI or 
fibrin in the cold. 
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Figure 1.3 Schematic representation of the interaction of the N-terminal Fib-1 region with 
the αC domain.  The numbered boxes represent the five FN fingers. This figure is reproduced 
from reference [3]. 
Dissertation objectives 
 
Studies have shown that fibrinogen-fibronectin complexes only exist in the plasma of 
patients with various inflammatory diseases. Few of these studies have described the properties 
of these complexes. Furthermore, although some studies have examined the interaction of FN 
with FI, the interactions of FN with  and ’ FI subspecies was not investigated. Therefore, the 
specific goals of this dissertation were to:  
a) Characterize the properties of a fibrinogen-fibronectin complex purified from human 
plasma of healthy individuals.  
b) Characterize the size distributions and hydrodynamic properties of the isolated complex 
and comparable mixtures of FI and FN. 
NH2 
COOH 
NH2 
COOH 
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c) Characterize the kinetics and mechanical properties of fibrin clots derived from the 
isolated complex and comparable mixtures of FI and FN. 
d) Characterize the biological activities of the isolated complex with an in vitro cell 
adhesion model. 
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Abstract 
 
We have developed a method for isolating a 1:1 fibrinogen-fibronectin complex from 
normal human plasma using a sequence of cryoprecipitation, ammonium sulfate fractionation, 
and DEAE Sepharose chromatography. SDS-PAGE under reducing condition showed both a 1:1 
stoichiometric ratio of pdFI to pdFN as well as a stoichiometric ratio of 1:1 of γ to γ’. Only 
γγpdFI was discernible to be present in the DEAE chromatographic fall-through.  The γγ’pdFI-
pdFN complex was non-covalent in nature as it was disrupted by affinity adsorption to Gelatin 
Sepharose where pdFN bound strongly and the disrupted γγ’pdFI fell through the 
chromatographic column. The FI and FN components of the complex migrated independently on 
native gel confirming its noncovalent nature. The second DEAE analysis of the gelatin 
Sepharose fall through demonstrated that the FI population capable of binding FN at room 
temperature was that containing the γγ’FI heterodimer. Surprisingly, the purified γγ’pdFI-pdFN 
complex was more broadly thermally stable than pdF1 preparations not containing pdFN and 
was also stable at physiologic pH, ionic strength and temperature.   
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Introduction  
 
The binding interactions of the general population of pdFN with pdFI have been studied 
in detail. Earlier studies showed that heparin could induce the formation of a cold-insoluble 
precipitate of fibrinogen and cold-insoluble globulin of plasma [1]. The cold-insoluble globulin 
is now known as fibronectin. In later studies, the main components of a pathologic plasma 
precipitate termed cryoglobulin made by treatment with thrombin of normal plasma were shown 
to be cold-insoluble globulin, fibrin and fibrinogen [2]. These studies showed that the binding of 
fibrinogen to cold-insoluble globulin was strong at 4
o
 C but only weakly binding at 22
o
 C. They 
went on to demonstrate that the COOH- terminal domain of the Aα chain of fibrin/fibrinogen is 
required for this interaction.  Smith and Von Korff initially described the presence of fibrinogen-
fibronectin complex in the plasma of patients with different inflammatory, infectious, or 
neoplastic diseases [3, 4]. Later analysis confirmed the existence of the complex in the plasma 
obtained from patients with dermatological diseases and ulcers [5, 6]. Using turbidity 
measurements, Mosesson and Stathukis elucidated the mechanism of cryoprecipitates formation 
and indicated that FN functions as a nucleus for precipitation of these complexes [7].  
Recently, Makogonenko et al [8] reported the results of a detailed study on the 
interactions of FN with FN free plasma-derived fibrinogen and also fibrin made from that same 
material. Using ELISA and Surface Plasmon Resonance, this FN free fibrinogen did not bind 
FN, but fibrin bound with high affinity. The authors used a variety of proteolytic fragments and 
recombinant derived domains of fibrin to demonstrate that FN binding was due to interaction 
with residues 221-391 of the αC domain. These results are consistent with the earlier reports and 
provide a more rigorous understanding of the structural basis for the broad interaction between 
the two proteins.  
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Niewiarowsk and Cierniewski have shown that significant amount of FN was 
incorporated into fibrin clot when blood plasma was treated with thrombin in the presence of 
calcium ions or EDTA [9]. The binding was dependent on temperature, concentration, and the 
presence of calcium ions. Binding occurred at a temperature of 20 °C and 37 °C, however, 
increased amount of FN was incorporated at 4 °C. Ruoslahti and Vaheri, on the other hand, have 
shown that the amount of FN incorporated into the clot is greatly influenced by ambient 
temperature [10]. The binding of FN to fibrin clot was observed at low temperature but such 
binding was prevented or reversed at 37 °C. FN was also bound to Sepharose-conjugated FI at 0 
°C but released by elevating the temperature.  
In this study we describe, for the first time, the purification of a FI-FN complex from 
human plasma of healthy individual by a sequence of cryoprecipitation, ammonium sulfate 
precipitation, and DEAE Sepharose chromatography. Results from this report provide significant 
insights into the structure and function of the complex.  
Materials and Methods 
 
Materials 
 
All reagents of highest purity were purchased from Sigma Chemical Company (St. Louis, MO) 
unless otherwise noted. Human plasma was donated by the U.S. Army Materials Command (Fort 
Detrick, MD). Human plasma fibrinogen depleted of fibronectin, plasminogen, and von 
Willebrand Factor was purchased from Enzyme Research Laboratories (South Bend, IN). DEAE 
Sepharose Fast Flow and gelatin Sepharose were purchased from GE healthcare (Uppsala, 
Sweden). Human fibrinogen was purified from plasma by cryoprecipitation followed by two 
ethanol precipitation as previously described [11]. Human fibronectin was isolated from plasma 
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on Gelatin Sepharose as previously described [12]. Anti-mouse fibronectin monoclonal IgG1 
antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-human FXIIIB 
monoclonal antibody was purchased from Green Mountain Antibodies (Burlington, VT). Anti-
human FXIIIA polyclonal antibody was bought from US Biologicals. Anti-human α2AP 
polyclonal antibody HRP was bought from US Biologicals. Anti-mouse IgG (whole molecule) 
peroxidase conjugate and anti-sheep IgG peroxidase conjugate were obtained from Sigma 
Chemical Company.  
Isolation of fibrinogen-fibronectin complex 
 
The complex was isolated from human plasma using cryo and ammonium sulfate 
precipitation steps followed by anion-exchange chromatography on DEAE Sepharose. The 
procedures are described below and summarized in Figure 2.1. 
Cryoprecipitation 
 
Fifteen units of human plasma (12.65 liters) that had been frozen at -80 °C were thawed 
slowly at 4 °C. The plasma was centrifuged in a Sorvall RC-5C Plus Superspeed Centrifuge 
(Kendro Laboratory, Newtown, CT) at 4000 rpm for 20 min at 4 °C. The supernatant was stored 
at -80 °C for future purification of fibronectin and other plasma-derived proteins. The fibrinogen-
rich cryoprecipitate was re-suspended in a re-suspension buffer containing 20 mM tris-base, 55 
mM sodium citrate, 27 mM lysine, PH 6.8 for 3 hours at room temp. Viral inactivation was 
carried out by adjusting the re-suspended cryoprecipitate solution to 0.15% (V/V) TNBP and 
0.5% (V/V) Triton X-100. The solution was stirred at room temp for one hour.  
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Ammonium Sulfate Precipitation  
 
The solvent-detergent treated solution was chilled to ~4 °C on ice then adjusted to 1 M 
ammonium sulfate by adding a 4 M stock solution. The sample was incubated on ice for 30 min 
then centrifuged at 4000 rpm at 4 °C for 20 min. The supernatant was discarded and the 
precipitate was re-suspended in the re-suspension buffer at room temp. The solution was 
dialyzed overnight against dialysis buffer containing 20 mM sodium citrate, 100 mM NaCl, pH 
7.4. The solution was transferred to a fresh buffer and dialysis continued with two changes. The 
dialyzed solution was centrifuged for 20 min at 4000 rpm at 25 °C. Any remaining pellet was 
discarded and sample was analyzed by BCA protein assay, reduced and nonreduced SDS-PAGE, 
and Western blots analysis. 
Anion-exchange Chromatography 
 
Anion-exchange chromatography of ammonium sulfate precipitated fibrinogen solution 
was carried out on a 2.7 cm by 200 cm DEAE Sepharose Fast Flow (GE healthcare Bio-
Sciences) column. The run was performed at room temperature using the BioCAD workstation 
chromatography System (Applied Biosystems) with an automated gradient controller. The run 
was monitored by the continuous measurement of the effluent absorbance at 280 nm. The sample 
was applied to the DEAE Sepharose column equilibrated with the dialysis buffer. To eliminate 
nonadsorbed and weakly bind proteins, the column was washed with 2 column volume of 
dialysis buffer until absorbance at 280 nm returned to the base line. Bound protein was eluted 
with a linear gradient of 0.1 M to 1.0 M NaCl in 20 sodium citrate and pH 7.4 buffers. Fractions 
were collected, pooled, and dialyzed versus dialysis buffer. 
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Gelatin Sepharose Chromatography 
 
Ammonium sulfate precipitated fibrinogen was fractionated by affinity chromatography 
using Gelatin Sepharose 4B (GE healthcare). The run was done on 1.6 cm by 100 cm gelatin 
Sepharose 4B column using the BioCAD workstation chromatography system. The column was 
equilibrated with a TEC buffer containing 50 mM Tris-Base, 50 mM 6-aminocaproic acid, 20 
mM sodium citrate, PH 7.5. The fibrinogen sample diluted with the same buffer was applied to 
the equilibrated column and washed with a 3 column volume of the equilibration buffer until 
absorbance at 280 nm returned to the base line. The column was further washed with a 3 column 
volume of the same buffer containing 1 M NaCl to remove nonspecific binding proteins. Still 
retained protein was desorbed with a step elution of the same equilibration buffer containing 1 M 
NaCl and 6 M urea. Fall through fractions were collected and dialyzed against dialysis buffer (20 
mM citrate, 100 mM NaCl, PH 7.4). The elution portion was dialyzed versus a buffer containing 
25 mM Tris-base, 150 mM NaCl, pH 7.5. Samples were analyzed by SDS-PAGE and Western 
blots analysis. 
SDS-PAGE Analysis 
 
The purity of the isolated fibrinogen was examined by SDS-PAGE under both reducing 
and nonreducing conditions. Samples were analyzed on 4-12% NuPAGE Bis-Tris Mini Gels 
(Life Technologies, Grand Island, NY) using NuPAGE LDS sample buffer. Reduced samples 
were treated with NuPAGE sample reducing agent. After 10 minutes incubation at 74 °C, 
samples were loaded onto the gel and run using 2-(N-morpholino) ethanesulfonic acid (MES) for 
one hour at 200 volts. Gels were stained with colloidal blue (Invitrogen, Carlsbad, CA).  
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Samples were also analyzed under non-denaturing condition in 3-12% NativePAGE 
Novex Bis-Tris Gels (Invitrogen). Samples were mixed with the NativePAGE Sample Buffer 
and run using the anode and cathode buffers for 115 minutes. Samples were visualized with 
colloidal blue. 
Western Blot Analysis 
 
Samples were analyzed on 4-12% NuPAGE Bis-Tris Mini Gels (Life Technologies) 
under reducing or non-reducing condition. Gels were electroblotted onto polyvinylide fluoride 
(PVDF) membranes (Millipore, Billerica, MA) for 45 min at 25 volts. Blots were blocked in 50 
ml of 5% casein in TBST (Tris-buffered Tween-20) for 30 minutes at room temperature. Blots 
were incubated with the following antibodies: (a) anti-plasma fibrinogen antibody (Green 
Mountain Antibodies, Burlington, VT); (b) anti-plasma fibronectin monoclonal antibody (Santa 
Cruz Biotechnology, Santa Cruz, CA); (c) anti-plasma fibrinogen α-chain polyclonal antibody 
(Sigma Aldrich, Saint Louis, MO); (d) anti-plasma fibrinogen β-chain polyclonal antibody 
(Sigma Aldrich); (e) anti-plasma fibrinogen γ-chain monoclonal antibody (Sigma Aldrich). Blots 
developed with anti-plasma fibrinogen, anti-plasma fibronectin, and anti-plasma fibrinogen γ-
chain antibodies were subsequently detected with an anti-mouse IgG peroxidase conjugate 
(Sigma Aldrich). Blots developed with anti-plasma fibrinogen α-chain and anti-plasma 
fibrinogen β-chain antibodies were probed with an anti-rabbit IgG peroxidase conjugate (Sigma). 
Blots were visualized with DAB/Metal concentrate and stable peroxide substrate buffer (Thermo 
Scientific, Rockford, IL) or chemiluminescence using Immun-Star HRP enhancer and peroxide 
buffer (Bio-Rad Laboratories, Hercules, CA). 
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       4000 rpm for 25 min at 4 °C 
              Virus inactivation 
 (0.15% TNBP + 0.5% Triton X-100) 
  Thaw at 4 °C 
                                            Resuspend in 
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Ammonium sulfate precipitation 
               Centrifugation  
       4000 rpm for 10 min at 4 °C 
                                            Resuspend in 
 (20 mM Tris-Base, 55 mM sodium citrate, 27 mM lysine, PH 6.8) 
  
DEAE Sepharose chromatography 
                              Dialysis  
(20 mM sodium citrate, 100 mM NaCl, PH 7.4) 
pdFI-pdFN complex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Purification procedure of fibrinogen-fibronectin complex 
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Dissociation of ’FI-FN complex by affinity Chromatography 
 
The ’pdFI-pdFN complex was separated by affinity chromatography using Gelatin 
Sepharose 4B (GE healthcare, Uppsala, Sweden). The chromatography was carried out on 1.6 
cm by 200 cm Gelatin Sepharose 4B column at room temperature. The flow rate, pressure, and 
absorbance at 280 nm were monitored using BioCAD workstation chromatography system. The 
column was equilibrated with the dialysis buffer (20 mM citrate, 100 mM NaCl, PH 7.4). The 
sample was applied to the column and washed with a 3 column volume of the dialysis buffer. 
Absorbed protein was eluted with a step elution of the dialysis buffer containing 6 M urea. 
Samples were collected and dialyzed against 25 mM Tris-base, 150 mM NaCl, pH 7.5 buffer. 
Isolation of γγ and γγ’ fibrinogen containing species 
 
Cryoprecipitated pdFI, ammonium sulfate precipitated pdFI, DEAE Sepharose fall 
through (pdFI), and gelatin Sepharose fall through (’pdFI) were resolved into γγ and γγ’ 
fibrinogen subspecies by using a method previously described by Siebenlist [13]. Briefly, FI 
samples were subfractionated into γ-chain species by ion-exchange chromatography on DEAE 
Sepharose. The analysis was performed on 27 mm × 205 mm DEAE Sepharose column at room 
temperature using BioCAD system. Fibrinogen samples were dialyzed against or diluted with 
buffer A containing 39 mM Tris-Base, 5 mM H3PO4, pH 8.55 then loaded into the DEAE 
Sepharose column equilibrated with the same buffer. After the column was washed with buffer A 
until the absorbance at 280 nm returned to the base line, bound proteins were eluted with a 
gradient of buffer A and buffer B containing 500 mM Tris-Base, 500 mM H3PO4, pH 4.2. 
Elution fractions were pooled, dialyzed against dialysis buffer (20 mM sodium citrate, 100 mM 
NaCl, pH 7.4), and concentrated by ultracentrifugation on Amicon centrifugal filter units.  
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Results  
Isolation and characterization of ’pdFI-pdFN complex 
 
Cryoprecipitation, AS precipitation and DEAE chromatography 
 
The SDS-PAGE gel electrophoresis analysis of plasma FI isolated by cryoprecipitation 
followed by ammonium sulfate precipitation is shown in Figure 2.2. Cryoprecipitated FI under 
reduced condition (lane 4) reveals three distinct bands with apparent molecular weights of ~67, 
54, 47 kDa corresponding to the well-established α, β, and γ chains of FI. In addition, the same 
lane exhibits a minor high molecular weight band of ~220 kDa characteristic of FN monomer. 
Ammonium sulfate precipitated FI under reduced condition (lane 5) show similar pattern as 
cryoprecipitated fibrinogen. However, the primary difference is that the ammonium sulfate 
precipitated FI contains higher ratio of FN to FI subunits than cryoprecipitated FI. FN is not 
detectable in the human fibrinogen standard purchased from Enzyme Research. 
Ammonium sulfate precipitated FI was applied to a column of DEAE Sepharose at 25 ̊C 
and pH 7.4. After washing with dialysis buffer until absorbance at 280 nm returned to the 
baseline, absorbed protein was eluted with a linear gradient of 0.1 M to 1 M NaCl. The results 
are depicted in Figure 2.3. The absorbance profile exhibited two major peaks. The first large 
peak of absorbance corresponds to the stepwise flow through region while the relatively small 
but symmetrical peak represents the gradient elution region.  
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Figure 2.2 Gel electrophoresis evaluation of plasma fibrinogen purified by 
cryoprecipitation and ammounium sulfate precipitation. Samples were analyzed under 
reducing condition on 4-12% SDS-PAGE and stained with colloidal blue. Lane 1: molecular 
weight marker; lane 2: pdFI (reference); lane 3: pdFN (reference); lane 4: cryoprecipitated pdFI; 
lane 5: ammonium sulfate precipitated pdFI. 
 
The SDS-PAGE analysis of ammonium sulfate precipitated fibrinogen fractionation on 
DEAE Sepharose is shown in Figure 2.4.  It is clear from the figure that the majority of the pdFI 
in the starting material was not absorbed at pH 7.4 by the DEAE Sepharose resin. The DEAE 
Sepharose fall through under reduced condition is devoid of fibronectin and shows only the three 
peptide chains α, β, and γ of fibrinogen. Sample eluted from DEAE Sepharose under reducing 
condition revealed the three subunits of fibrinogen in addition to a high molecular weight band 
corresponding to the fibronectin. The staining intensities of these bands and their co-elution 
indicate a 1:1 stoichiometric ratio of fibrinogen-fibronectin complex as well as fibrinogen and 
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’ chains. Based on BCA protein assay, the bound fraction represented ~10 percent of the 
starting material. 
 
Figure 2.3 Fractionation of ammonium sulfate precipitated pdFI on DEAE Sepharose 
chromatography.  Chromatography was performed in 2.7 cm by 20 cm DEAE Sepharose 
column. The broad peak represents the material not retained by the column while the small 
symmetrical peak represents the eluted material. Absorbance at 280 nm (red line), conductivity 
(blue line), and pH (green line) were monitored with the BioCAD system.  
The isolated complex was analyzed under non-denaturing condition on 3-12% native gel. 
Results are shown in Figure 2.5. Both the isolated complex and mixtures of FN with FI species 
migrated as two bands. The upper band corresponds to the FN molecule, while the lower band 
represents FI species. Both FI and FN components of the isolated complex migrated slightly 
slower than the corresponding individual proteins. These data suggest that the molecule is 
noncovalent in nature.  
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Figure 2.4 Gel electrophoresis evaluation of plasma fibrinogen-fibronectin complex 
purified by DEAE Sepharose chromatography.  Samples were analyzed under reducing 
condition on 4-12% SDS-PAGE and stained with colloidal blue. Lane 1: molecular weight 
marker; lane 2: pdFI (reference); lane 3: pdFN (reference); lane 4: ammonium sulfate 
precipitated FI (loading sample); lane 5: DEAE fall through; lane 6: DEAE elution product 
(’pdFI-pdFN complex). 
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Figure 2.5 Native gel electrophoresis analysis of ’pdFI-pdFN complex.  Samples were 
analyzed under native condition on 3-12% NativePAGE and stained with colloidal blue. Lane 1: 
pdFN; lane 2: pdFI; lane 3: ’pdFI; lane 4: rFI; lane 5: ’rFI; lane 6: ’pdFI-pdFN; lane 7: 
a mixture of pdFI and pdFN; lane 8: a mixture of ’pdFI and pdFN; lane 9: a mixture of rFI 
and pdFN; lane 10: a mixture of ’rFI and pdFN. 
Cryoprecipitated FI, ammonium sulfate precipitated FI, and the isolated complex were 
subjected to immunoblot analysis on Western blots. Results are shown in figures 2.6 and 2.7. 
Anti-fibrinogen blot (Figure 2.6 panel A) confirmed the identity of bands corresponding to the α, 
β, and -chains of fibrinogen detected with SDS-PAGE analysis. The identity of FN bands was 
confirmed by an anti-fibronectin blot (Figure 2.6 panel B) which also showed that the isolated 
complex contained a higher percentage of FN than cryoprecipitated and ammonium sulfate 
precipitated FI. This indicates that the ammonium sulfate precipitation and DEAE 
chromatography steps enriched the amount of FN in the final product. Anti-fibrinogen α-chain 
(Figure 2.7 panel A) and anti-fibrinogen β-chain (Figure 2.7 panel B) revealed that these chains 
are intact in the three samples. Anti-fibrinogen γ-chain, which is able to cross-react with ’-
chain, revealed that the ’ content is higher in the isolated complex compared to the other two 
products.  
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Figure 2.6 Anti-fibrinogen (A) and anti-fibronectin (B) western blot analyses of ’pdFI-
pdFN complex.  Reduced samples were analyzed in 4-12% SDS-PAGE and electrophoretically 
transferred to PVDF membrane. Blots were developed as described in the material methods. 
Lane 1: molecular weight marker; lane 2: pdFI (reference); lane 3: pdFN (reference); lane 4: 
cryoprecipitated pdFI; lane 5: ammonium sulfate precipitated pdFI; lane 6: ’pdFI-pdFN 
complex. 
 
 
 
Figure 2.7 Anti-fibrinogen alpha chain (A), anti-fibrinogen beta chain (B), and anti-
fibrinogen gamma chain (c) Western Blot analyses of ’pdFI-pdFN complex.  Reduced 
samples were analyzed in 4-12% SDS-PAGE and electrophoretically transferred to PVDF 
membrane. Blots were developed as described in the material methods. Lane 1: molecular weight 
marker; lane 2: pdFI (reference); lane 3: pdFN (reference); lane 4: cryoprecipitated pdFI; lane 5: 
ammonium sulfate precipitated pdFI; lane 6: ’pdFI-pdFN complex. 
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Gelatin Sepharose chromatography 
 
Additional experiments were conducted to determine whether the native complex can be 
isolated by affinity chromatography on gelatin Sepharose. The re-suspended ammonium sulfate 
precipitated FI was applied to a column of gelatin Sepharose. The gel electrophoresis profile of 
ammonium sulfate precipitated fibrinogen loaded into gelatin Sepharose is shown in Figure 2.8. 
Reduced 4-12% SDS-PAGE showed that the loading sample (lane 4) consist of the high 
molecular weight fibronectin and fibrinogen subunits. The flow through (lane 5) contains 
fibrinogen subunits and depleted of fibronectin. Fibronectin has been retained by the column due 
to its high binding affinity for collagen. The 6 M urea eluted fractions (lanes 8-10) contain 
fibrinogen-fibronectin complexes. Although, the ratio of fibrinogen to fibronectin in these 
complexes does not exhibit the same stoichiometry as DEAE eluate, there is association of 
fibrinogen with fibronectin. This dissociation of the complex by adsorption on gelatin Sepharose 
indicates that it’s noncovalent in nature. Due to its high affinity for gelatin, FN was retained by 
the column whereas FI fell through. This is in agreement with Engvall and Ruoslahti studies 
showing that the FI can be separated from FN using this chromatography [14]. Separate studies 
have demonstrated that the incorporation of FN into blood clot is completely inhibited by gelatin 
[15], indicating that gelatin and FI share the same binding site in FN or more likely that the two 
binding sites are located next to each other. In contrast, the 1:1 FI-FN complex from pathological 
plasma described by Nagamatsu at el was isolated by the affinity of FN on this column. 
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Figure 2.8 Fractionation of ammonium sulfate precipitated fibrinogen on gelatin Sepharose 
chromatography.  Samples were electrophoresed under reduced condition on 4-12% SDS-
PAGE then stained with colloidal blue. Lane 1: molecular weight marker; lane 2: pdFI 
(reference); lane 3: pdFN (reference); lane 4: loading sample (cryoprecipitated pdFI); lane 5: fall 
through; lane 6: wash; lanes 7 through 10: elution fractions. 
 
Dissociation of ’pdFI-pdFN complex by affinity Chromatography 
 
The ’pdFI-pdFN complex was disrupted by affinity chromatography on gelatin 
Sepharose. Sample of ’pdFI-pdFN complex was applied to gelatin Sepharose column at room 
temperature and washed with TEC buffer containing 1 M NaCl until absorbance reached 
baseline. Protein retained by the column was eluted with stepwise of TEC buffer containing 6 M 
urea. The chromatographic analysis is shown in Figure 2.9. The broad large peak of absorbance 
is the flow through region, while the small symmetrical peak of absorbance is the gradient 
elution.  
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Figure 2.9 Disruption of ’pdFI-pdFN complex by affinity chromatography on gelatin 
Sepharose.  Chromatographic analysis was performed on a gelatin Sepharose column (1.6 cm by 
10 cm) at room temp. First peak: gelatin Sepharose fall through and wash fractions; second peak: 
gelatin Sepharose elution fractions. Absorbance at 280 nm (red line), conductivity (blue line), 
and pH (green line) were monitored with the BioCAD system. 
 
The SDS-PAGE gel electrophoresis analysis of the purification products is shown in 
Figure 2.10. The loading sample (lane 4) consists primarily of FN and FI subunits. The flow 
through (lane 5) is devoid of fibronectin because of the high binding affinity it exhibits towards 
gelatin. The gelatin Sepharose elution product is shown in lane 6. It’s depleted of fibrinogen 
species indicating that the high binding affinity of FN for gelatin Sepharose may displace a large 
portion of FN associated with FI. 
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Figure 2.10 Gel electrophoresis evaluation of disrupting plasma ’pdFI-pdFN complex on 
gelatin Sepharose chromatography.  Samples were analyzed under reducing condition on 4-
12% SDS-PAGE and stained with colloidal blue. Lane 1: molecular weight marker; lane 2: pdFI 
(reference); lane 3: pdFN (reference); lane 4: ’pdFI-pdFN complex; lane 5: gelatin Sepharose 
fall through (’pdFI); lane 6: gelatin Sepharose elution product (pdFN ). 
 
Isolation of γγ and γγ’ fibrinogen containing species 
 
Plasma FI, flow through from the DEAE step, and flow through from the gelatin 
Sepharose run of the DEAE bound material were subjected to the DEAE chromatography 
conditions described by Siebenlist et al. The results are shown in Figure 2.11. Plasma FI (panel 
A) was resolved into two peaks, a dominant sharp peak followed by smaller one. SDS-PAGE gel 
electrophoresis analysis (Figure 2.12) revealed that the first peak consist off the γγpdFI 
subspecies while the second peak contain the γγ’pdFI subspecies. The flow through of the first 
DEAE Sepharose exhibited two peaks, predominate peak followed by a faint one. SDS-PAGE 
analysis showed that both peaks contain exclusively γγpdFI subspecies. The flow through of the 
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gelatin Sepharose revealed smaller peak that eluted much later and consist of the γγ’pdFI 
subspecies. This results clearly demonstrate that the pdFI bound to pdFN at room temperature is 
composed of the γγ’pdFI subspecies. 
 
 
Figure 2.11 Isolation of  and ’fibrinogen subspecies by DEAE Sepharose 
chromatography.   Samples were fractionated on 27 mm × 205 mm DEAE Sepharose column 
using a gradient elution of buffer A and B at room temp. Absorbance at 280 nm (red line), 
conductivity (blue line), and pH (green line) were monitored with the BioCAD system. Panel A: 
pdFI (Enzyme Research); panel B: pdFI flow through from the first DEAE column; panel C: 
pdFI flow through from the gelatin Sepharose; panel D: composite. 
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Figure 2.12 Gel electrophoresis analysis of  and ’ fibrinogen subpopulation resolved by 
DEAE Sepharose. Samples were analyzed under reducing condition on 4-12% SDS-PAGE and 
stained with colloidal blue. Lane 1: molecular weight marker; lane 2: pdFI (reference); lane 3: 
pdFN (reference); lane 4: original DEAE Sepharose fall through (pdFI); lane 5: gelatin 
Sepharose fall through (’pdFI).  
 
Discussion  
 
The present investigation is in contrast with earlier studies that shown complexes of 
fibrinogen and fibronectin exist only in the plasma of patient with inflammatory and infectious 
diseases. We have demonstrated that a 1:1 fibrinogen-fibronectin complex can be purified from 
normal human plasma of healthy individual using a sequence of cryoprecipitation, ammonium 
sulfate precipitation, and anion-exchange chromatography on DEAE Sepharose. The second 
DEAE analysis of the gelatin Sepharose fall through demonstrated that the FI component of the 
complex is composed exclusively of the γγ’ heterodimer.  
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The ammonium sulfate precipitated FI contained higher percentage of fibronectin 
compared to cryoprecipitate or commercial FI preparations. This result is not completely novel in 
that Bar [16] reported that different methods of FI isolation differ in their fibronectin content. 
However, it was of interest that the ammonium sulfate isolation done at room temperature 
yielded the higher fibronectin content relative to the cryoprecipitate isolation which was done at 
4
o
C. Ammonium sulfate is known to be a relatively gentle precipitation method capable of 
preserving the integrity of protein-protein complexes [17]. The result indicates the presence of a 
room temperature stable complex of fibrinogen and fibronectin. Our studies also show that even 
the relatively low ratio of fibronectin to fibrinogen in the ammonium sulfate fractionated 
material is able to prevent aggregation/precipitation of the fibrinogen when at a high 
concentration at 4
o
 C. 
When the ammonium sulfate fraction was applied to DEAE Sepharose in an attempt to 
remove solvent detergent, ~10% of the applied protein bound the column. The flow through 
contained the majority of the FI and was depleted of FN. The eluate contained a mixture of FI 
and FN in what appeared to be a 1:1 stoichiometric ratio. This result indicates that the FI 
associated with the DEAE resin may be due to its interaction with FN. To our knowledge, this is 
the first report of binding of fibrinogen as opposed to fibrin from normal human plasma to 
fibronectin at room temperature.  
The gamma prime hetero-dimeric subpopulation of fibrinogen (’FI) has several unique 
functional attributes arising from its 25 additional amino acids on the carboxyl terminal domain 
of the gamma chain [18]. The ’pdFI constitutes about 10 % of the total fibrinogen. Importantly, 
it also exhibits a much stronger anionic exchange adsorption behavior due to two more sulfation 
sites than the FI which represents the remaining 90% of the total FI. For example, using DEAE 
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chromatography of fibrinogen loaded at pH 8.55 and an elution gradient to pH 4.2, Siebenlist et 
al were able to resolve fibrinogen consisting of the γ chain from that containing the alternative 
splice variant γ/ [13]. They went on to show that factor XIII binding was restricted to the 
subpopulation of fibrinogen containing the splice variant. The study also demonstrates the 
importance of using a relatively high pH to achieve binding of the majority of a fibrinogen 
sample to DEAE. However, the conditions used here, allowed us to detect and isolate the 
apparent fibrinogen- fibronectin complex. It is possible that there is also a subset of fibrinogen 
that is capable of binding fibronectin at room temperature.  
The fibrinogen used in the studies of Makogonenko et al was obtained from Enzyme 
Research. Although the method of purification is not provided by the supplier, they do specify 
that it is devoid of fibronectin. That component of fibrinogen capable of binding fibronectin at 
room temperature could have been removed during purification. This possibility is supported by 
our observation that when this material was subjected to gelatin-Sepharose chromatography, 
there was no detectable fibrinogen or fibronectin bound to the column (data not shown). 
The interaction of fibrinogen with fibronectin was confirmed by gelatin Sepharose 
chromatography. The re-suspended ammonium sulfate precipitate was applied to the affinity 
resin. The flow through was depleted of fibronectin and contained the majority of the FI. The 
eluate contained what appeared to be a sub- stoichiometric ratio of FI to fibronectin but did 
contain FI. The fact that the stoichiometry of FI to FN was reduced in the gelatin binding fraction 
relative to what was observed with the DEAE may be due to competition between the gelatin and 
fibrinogen for binding sites on fibronectin. The displacement of pdFI by gelatin suggested that FI 
binding site in FN is either located close to or the same as that for gelatin. Indeed, examining the 
structure of FN reveals that both FI and gelatin binding sites are located in close proximity to 
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each other. There are 5 so called F1 structural repeats in the amino terminal region and another 3 
in the carboxyl terminal region of fibronectin. These two regions are thought to be the fibrin 
binding domains with the major fibrin binding region located in the amino terminal domain. 
Rostagno showed that it was repeats 4 and 5 in the amino terminal region that were responsible 
for binding [19]. These are immediately adjacent to the collagen/gelatin binding domain of 
fibronectin.  
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Chapter 3 Characterize the size distribution and hydrodynamic properties of 
the isolated complex and comparable mixtures of FI and FN 
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Abstract  
 
In this section, we estimated the molecular distribution and hydrodynamic properties of 
the isolated ’pdFI-pdFN complex utilizing different techniques that include size exclusion 
chromatography (SEC), dynamic light scattering (DLS), and analytical ultracentrifugation 
(AUC). The properties of the native complex was compared to that of free FN, unfractionated FI, 
 and ’ FI subspecies, and equimolar mixtures of FN with FI species. Results from SEC 
showed that in 200 mM NaCl the complex is a more compact form than FI alone. SEC also 
revealed that FN interact more strongly with ’ than  FI. The molecular distribution of the 
complex can be duplicated with a mixture containing an excess molar of ’FI with FN. 
DLS showed that the native complex was polydisperse molecules when analyzed in high 
ionic strength and denaturing conditions. At higher ionic strength and chaotropic condition, the 
complex displayed a larger hydrodynamic radius than the value obtained in lower ionic strength 
solution. This indicate that the native ’pdF-pdFN complex is a more compact form at low ionic 
strength but adopt and extended conformation in high salt and denaturing conditions. The 
hydrodynamic properties of the ’pdFI-pdFN complex depend on the conformational changes of 
FN. At physiologic ionic strength and pH, both  and ’ FI appeared as polydisperse molecules 
with larger hydrodynamic radius. However, the average hydrodynamic radius were decreased 
when an equimolar amount of FN was added, suggesting that FN interacts with both FI 
subspecies.  
When analyzed on AUC, the native complex displayed two peaks with sedimentation 
constants corresponding to the individual FI and FN. The sedimentation velocity profiles of the 
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mixtures of pdFI plus pdFN and ’pdFI plus pdFN appear to match the profile of the native 
complex. 
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Introduction 
 
Very few studies have investigated the hydrodynamic properties of FI-FN complexes 
from pathological plasma. For example, Matsuda described the properties of cryofibrinogen 
isolated from the plasma of male patient with leg dermal ulcers. When placed on ice, the 
cryofibrinogen formed precipitate that readily re-solubilized at 37 °C. Ultracentrifugation 
showed that the cryofibrinogen dissociated at ambient temperatures to form individual FI and FN 
components. Amino acid and gel electrophoresis revealed that the cryofibrinogen is a simple 
complex between normal plasma FI and normal plasma FN. However, quasielastic light 
scattering and circular dichroism analysis indicate that the cryofibrinogen possesses unique 
properties that are different from those of normal plasma FI and FN mixtures [1]. Nagamatsu and 
colleagues used affinity chromatography on gelatin-Sepharose to isolate a 1:1 complex of 
fibrinogen and fibronectin from plasma of patients with rheumatoid arthritis [2]. This isolated 
complex exhibited a compact hydrodynamic property as measured by dynamic light scattering. 
Here we describe the hydrodynamic properties and size distribution of the native complex 
and mixtures of FI and FN utilizing techniques that include SEC, DLS, and AUC. DLS studies 
were performed at 25 °C using a DynaPro Molecular Sizing instrument equipped with an 830 nm 
laser source (Wyatt, Santa Barbara). Temperature in the MicroSampler is controlled by a Peltier 
effect heat pump that maintains a temperature with an accuracy of better than 1 °C in the range -
4 to 60 °C. The Dynapro instrument consisted of a semiconductor diode light source that emits a 
laser of ~ 830 nm wave length. Light scattered by the sample is converted by an actively 
quenched solid State single Photon Counting Module into electrical pulses. Figure 3.1 shows the 
setup of DynaPro instrument. The translational diffusion coefficient (D) of the molecule is 
derived from the intensity of the scattered light by a mathematical process known as 
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autocorrelation. The hydrodynamic radius (R) is derived from the diffusion coefficient using the 
Stokes-Einstein equation. Data were analyzed using Dynamics V6 software.  
 
Figure 3.1 Block diagram of DLS instrument 
Sedimentation equilibrium and velocity experiments were performed in a Beckman 
Coulter Proteome Lab XL-1 (Beckman Coulter). The instrument measures the concentration 
distributions of a protein under high centrifugal forces. The concentration distributions in the 
ProteomeLab system are determined by a combination of absorbance and interference 
(refractive) optical systems. The optical system consists of high-intensity xenon flash lamp that 
emits light in the UV/VIS range from 190 to 800 nm wavelength. The interference optical system 
contains laser diode light source, imaging optics, and a charge-coupled device detector. The 
system provides image of the cell by measuring the refractive index difference between sample 
and reference at the radial position. A diffusion pump or turbomolecular pump in series with a 
mechanical vacuum pump is used to reduce chamber pressure to below 5 microns. A solid state 
thermoelectric refrigeration and heating system is used to control the operating temperature in 
the range 0 to 40 °C with an accuracy of ± 0.3 or ± 0.5 °C. 
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Methods 
 
Size Exclusion Chromatography 
 
The molecular size distribution of the isolated ‘pdFI-pdFN complex was determined by 
SEC at room temperature. The analysis was performed on Knauer high pressure liquid 
chromatography (HPLC) system (Advance Scientific Instruments, Berlin, Germany) consisted of 
Knauer pump equipped with a sample injection valve, Conductivity meter, Smartline UV 
detector 2600, and fraction collector. ChromGate V3.1.7 Knauer Instrument Control Software 
was used to set and control pressure, flow for pump, wavelength for detector, and monitor these 
in real-time. Plasma  and ’ FI subspecies, FN, and the purified ‘pdFI-pdFN complex were 
exchanged into SEC buffer containing 20 mM sodium citrate, 200 mM NaCl, pH 7.0 and filtered 
through 0.22 μm Nylon filter. 180 μg of each sample was subjected individually to 10 mm × 300 
mm Superose 6 column (GE Healthcare, Uppsala, Sweden) equilibrated with SEC buffer. The 
flow rate was set at 0.5 ml/min for 60 min run duration and absorbance was monitored at 280 
nm. 1 min fractions were collected and analyzed by SDS-PAGE, Western blotting, and DLS. 
EZChrom Elite software was used to analyze the data. 
DLS 
 
SEC was used to prepare plasma derived fibrinogen (Enzyme Research, South Bend, IN), 
pdFN, and the purified ’pdFI-pdFN complex. Elutes from Superose 6 column were pooled and 
exchanged into different buffers that include100 mM NaCl, 150 mM NaCl, 1 M NaCl, and 6 M 
urea. To eliminate any potential contaminants such as dust and impurities, all samples were first 
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filtered through 0.22 µm Nylon membrane filter (VWR International, Radnor, PA) then through 
0.02 µm disposable syringe membrane filter (Whatman, Florham, NJ). 
The structure and molecular size of ‘pdFI-pdFN complex was determined by DLS 
using Protein Solutions DynaPro99 Titan with Temperature Controlled MicroSampler (Wyatt 
Technology Corp, Santa Barbara CA). Measurements were done at constant temperature of 25 
°C. Samples were analyzed under different concentrations (1 to 5 mg/ml) and solvent conditions. 
20 µl of protein sample was transferred to the DynaPro cell and inserted in the sample chamber. 
A further dilution was carried out if the protein sample aggregated or precipitated. A total of 20 
acquisitions of 10 seconds long were obtained for each measurement. Samples were analyzed in 
triplicate and the scattering parameters values were averaged. Data gathered by the DynaPro 
Titan instrument was analyzed using Dynamics software to determine the hydrodynamic 
properties. 
Analytical Ultracentrifugation 
 
Sedimentation velocity 
 
Individual proteins (γγ‘pdFI, pdFN), protein mixtures (γγ‘pdFI + pdFN) and a purified 
native complex (γγ‘pdFI-pdFN) were analyzed by sedimentation velocity experiments performed 
on an Optima XL-I analytical ultracentrifuge (Beckman coulter, Inc.) equipped with an eight-
hole An50Ti rotor. Prior to analysis, proteins were dialyzed against 50 mM tris containing 150 
mM NaCl, 1.1 mM CaCl2, 0.6 MgCl2, pH 7.5. The individual proteins and protein mixtures (400 
µl) were loaded into the sample compartment of a double-sector cell. The reference compartment 
was filled with 430 µl of the dialysate buffer. Sample cells were then incubated at 20 
o
C in the 
rotor chamber for 2 h under vacuum. After 2 h of incubation, samples were sedimented at 35,000 
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rpm. A total of 250 absorbance scans (280 nm) at 3.5 min intervals were collected. Absorbance 
values ranged from 0.5-0.7 for the different samples. The data were analyzed by SEDFIT version 
10.58d (PMID: 10692345) using the continuous c(s) distribution model and allowing the 
frictional ratio to float.  
Sedimentation equilibrium 
 
The oligomeric state of individual proteins (γγ‘pdFI, pdFN), protein mixtures (γγ‘pdFI + 
pdFN) and a purified native complex (γγ‘pdFI-pdFN) were determined at 20°C by sedimentation 
equilibrium using an Optima XL-I analytical ultracentrifuge (Beckman Coulter, Inc.). Proteins 
were dialyzed into 20 mM sodium citrate (pH 7.4) containing 100 mM NaCl. The sample cells 
were loaded with 110 µl of each protein (0.5 mg/ml concentrations), and reference cells were 
filled with the dialysis buffer. Radial scans were collected at 280 nm after 22 h at rotor speeds of 
3,000, 4,000, 6,000, and 8,000 rpm. Data from the three different rotor speeds were fit by global 
analysis to an equation describing a single species model using Origin 6.0. Partial specific 
volumes of 0.7235 and 0.7281 were calculated by SedTerp for FN and γγ‘FI, respectively, and 
were used for the best-fit analysis. The solvent density of the buffer was calculated to be 1.0039 
g/ml. 
Statistical analysis 
 
Data of repeated measurements were expressed as mean and standard deviation. 
Differences in hydrodynamic radius were analyzed by one-way Analysis of variance (ANOVA) 
using the software GraphPad Prims, version 5.0 (GraphPad Software, San Diego, CA). P values 
lower than 0.05 were considered to indicate statistical significance. 
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Results 
 
SEC 
 
The structure and molecular mass of the native ’pdFI-pdFN complex was determined 
by size exclusion chromatography at room temperature. 180 µg of purified samples of pdFI, 
’pdFI, pdFN, and ’pdFI-pdFN complex were subjected individually to Superose 6 column in 
200 mM NaCl citrate-buffered saline, pH 7.0. Figure 3.2 shows the elution profile of the three 
samples. Free  and ’ pdFI were eluted as sharp peaks centered at 21.4 and 21.5 min, 
respectively whereas FN eluted later as a broad peak centered at 23.5 min. The earlier elution of 
FI variants, despite their smaller molecular weight, indicates a more linear conformation whereas 
FN molecules appear to adopt a more compact conformation. This agrees with previous 
investigations that have shown, at physiologic pH and salt condition, FN is more globular 
structure whereas FI tend to be more linear. Studies have shown that FN molecule is only 
partially extended in 200 mM NaCl in the absence of glycerol [3-5]. Therefore, the compact FN 
molecules are more flexible and penetrate pores of the gel more than the linear FI. It’s known 
that elongated protein can elute at a position twice the molecular weight of a globular protein [6].  
Similar to  and ’pdFI, the native complex eluted as sharp peak centered at 21.6 min 
with minor tailing peak that partially separated from the major form centered at 24.5 min. This 
indicates that at this physiologic pH and near physiologic ionic strength, the complex is a more 
compact form than the linear FI species.  
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Figure 3.2 size exclusion chromatography of pdFN, isolated complex,  and ’ pdFI 
species.  Samples were chromatographed at room temperature on a Superose-6 column at 0.5 
ml/min in citrate-buffered saline, pH 7.0. 
 
We also employed SEC to study the interactions of FN with plasma unfractionated FI, 
FI, and ’FI subspecies. The interactions were carried out in citrate-buffered saline at room 
temperature. A dose response curves was created by holding the mole of FN constant while 
varying the mole of ’FI. Samples of FN and ’FI were incubated in a rotating mixer for 2 
hours then loaded to the Superose 6 column. Figure 3.3 shows the elution profile of mixtures of 
’FI and FN from Superose 6 column using 200 mM NaCl step elution in 20 mM sodium 
citrate, pH 7.0. The elution of mixtures of ’pdFI and pdFN, at constant level of FN, were 
shifted towards the void volume and FN peak started to disappear when the percentage of ’FI 
in the mixture was increased. This disappearance of FN peak was proportional to the 
concentration of ’FI added. At lower level of ’FI (0.25, 0.5, and 1 molar ratio) the mixture 
showed two peaks with elution time similar to free ’FI and FN. When the molar ratio of ’FI 
'pdFI 
pdFI 
'pdFI-pdFN 
pdFN 
 
 
 
 
 
pdFI 
'pdFI 
'pdFI-pdFN 
pdFN 
 
 
 
 
58 
 
was increased above 1, the FN peak disappeared and the mixture eluted as a single peak 
suggesting that the two molecules interact to form complexes. The higher molecular weight 
complexes did not elute earlier (shift to the left) than the uncomplexed FI species, suggesting that 
the two molecules were folded into a compact structure. 
The interaction of pdFI with pdFN was monitored by holding the level of FN constant 
while varying the amount of pdFI. Results are displayed in Figure 3.4. All mixtures exhibited 
two peaks with elution times corresponding to the values of free FI and FN. In the 1.5:1 
FI:FN mixture, the majority of protein eluted at 21.7 min and the rest eluted as a broad tailing 
peak only partially separated from the predominant form. The FN peak was not completely 
disappeared even when the amount of FI was doubled. This suggests that FN dose not interact 
or interact differently with FI at room temp. 
 
Figure 3.3 Size exclusion chromatography of a mixture of ’pdFI and pdFN.  Samples were 
chromatographed at room temperature on a Superose-6 column at 0.5 ml/min in citrate-buffered 
saline, pH 7.0.  
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Figure 3.4 Size exclusion chromatography of a mixture of pdFI and pdFN.  Samples were 
chromatographed at room temperature on a Superose-6 column at 0.5 ml/min in citrate-buffered 
saline, pH 7.0. 
 
Dynamic light scattering 
 
We employed DLS to analyze the molecular sizes of native ’pdFI-pdFN complex under 
different buffer and solvent conditions that include (1) 100 mM NaCl, (2) 150 mM NaCl, (3) 1 
M NaCl, and (4) 6 M urea. DLS experiments were done using a Protein Solutions DynaPro99 
Titan with Temperature Controlled MicroSampler at a constant temperature of 25 ̊C. Proteins 
molecular weight and polydispersity estimations were calculated from data collected by the 
DynaPro Titan instrument using Dynamics software. The histogram from the regularization fit of 
the autocorrelation function graph shows the size distribution of the molecules at the different 
conditions. The polydispersity index provides a direct measure of the heterogeneity of each 
molecular species in sample. A polydispersity index below 20% means that the molecular 
species is monodisperse, otherwise it is heterogeneous.  
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The intensity and molecular distributions of the pdFN and ’pdFI-pdFN complex are 
presented Figure 3.5 and Table 3.1. The size distribution histogram shows that in the presence of 
100 mM NaCl, ’pdFI-pdFN complex appeared as a prominent peak with an average 
hydrodynamic radius of 8.6 ± 0.24 nm and intensity distribution of 94.5%. The polydispersity of 
23.9 ± 5.9% shows that the molecule is slightly polydisperse. Small population of large 
aggregates with a high molecular weight was also detected. Similar to the native complex, pdFI 
appeared slightly polydisperse but with larger hydrodynamic radius of 17.4 ± 0.4 nm. FN 
analyzed under similar condition appeared monodisperse (10.9 ± 5.7%) with a hydrodynamic 
radius of 9.5 ± 0.3 nm. This value is in agreement with the previous DLS data in which a 
hydrodynamic radius of 8.7 ± 0.2 nm was shown for FN in aqueous solution [7] and 8.6 ± 0.3 nm 
radius of gyration was shown for FN in physiological saline solution [8]. In addition, radius of 
gyration of 8.9 ± 0.3 nm and 9.5 ± 0.5 were obtained for FN from small-angle X-ray scattering 
and small-angle neutron scattering techniques respectively [9]. 
When salt concentration was increased to 1 M NaCl, pdFN and ’pdFI-pdFN complex 
molecules appeared larger than when 100 mM NaCl solution was used. The intensity and size 
distributions are shown in Figure 3.6 and Table 3.2. The average hydrodynamic radius increased 
to 11.1 ± 0.6 nm for the native complex and 13 ± 0.4 nm for pdFN. This indicates that exposing 
both molecules to the high-ionic strength buffer of 1 M NaCl caused them to undergo a 
conformational change from the compact structure to the more extended form. In contrast, the 
hydrodynamic radius of pdFI (17.4 ± 0.4 nm) was not affected by increasing the salt 
concentration. The measured hydrodynamic radius of pdFI is within experimental error to the 
value of 12 nm reported by Wasilewska [10] for pdFI in pH 9.5 solution. It’s known that FI 
exists as a compact structure under the high ionic strength and in the extended conformation at 
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low ionic strength [10]. The three proteins appeared slightly polydisperse in this high salt 
environment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Size distribution of pdFN and ’pdFI-pdFN complex.Analysis was determined by 
DLS at 25 ̊C in 100 mM NaCl solution, pH 7.4. 
 
Table 3.1 DLS parameters of pdFN, pdFI, and ’pdFI-pdFN complex analyzed in 100 mM 
NaCl. 
Item 
Hydrodynamic 
Radius  (nm) 
Polydispersity 
(%) 
Molecular 
weight estimate  
(kDa) 
Intensity 
distribution (%) 
pdFN 9.5 ± 0.3 10.9 ± 5.7 648 ± 48 98.1 
pdFI 17.4 ± 0.4 23.4 ± 0.6 2699 ± 137 81.9 
'pdFI-pdFN 8.6 ± 0.24 23.9 ± 5.9 514 ± 33 94.5 
62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Size distribution of pdFN, pdFI, and ’pdFI-pdFN complex.  Measurement was 
done by at 25 ̊C in 1 M NaCl citrate-buffered solution, pH 7.4. 
 
Table 3.2 DLS parameters of pdFN, pdFI, and ’pdFI-pdFN complex analyzed in 1 M 
NaCl.  
Item 
Hydrodynamic 
Radius  (nm) 
Polydispersity 
(%) 
Molecular 
weight estimate  
(kDa) 
Intensity 
distribution 
(%) 
pdFN 13 ± 0.4 22.1 ± 2.4 1451 ± 91 91.5 
pdFI 17.4 ± 0.4 23.6 ± 0.3 2680 ± 130 93.4 
'pdFI-pdFN 11.1 ± 0.6 25.8 ± 5.6 953 ± 118 88.3 
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The intensity and mass distributions of pdFI, pdFN, and ’pdFI-pdFN complex 
molecules analyzed in 6 M urea solution are shown in Figure 3.7 and Table 3.3. Compared to the 
size distribution seen in 1 M NaCl, both pdFN and pdFI appeared as more monodisperse while 
the native complex is slightly polydisperse. Both pdFN and the isolated complex appeared larger 
than when analyzed in 100 nm and 1 M NaCl solutions. The hydrodynamic radius was increased 
to 14.4 ± 0.3 nm for pdFN and 12.5 ± 0.6 nm for the isolated complex. This indicates that both 
proteins extend even more to the more linear conformation in this denaturing condition of 6 M 
urea. Our data is consistent with previous studies that showed FN converts to the linear polymer 
when exposed to a denaturing condition. Pelta demonstrated that the hydrodynamic radius of FN 
increased by a factor of 1.6 when analyzed in 8 M urea compared to the native physiologic 
condition [11]. pdFI showed a smaller hydrodynamic radius than the value observed in 100 mM 
and 1 M NaCl solutions.  
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Figure 3.7 Size distributions of pdFN, pdFI, and ’pdFI-pdFN complex.  Samples were 
analyzed by DLS at 25 ̊C in 6 M urea solution, pH 7.4. 
 
Table 3.3 DLS parameters of pdFN, pdFI, and ’pdFN-pdFN complex analyzed in 6 M 
Urea. 
Item 
Hydrodynamic 
Radius  (nm) 
Polydispersity 
(%) 
Molecular 
weight estimate  
(kDa) 
Intensity 
distribution 
(%) 
pdFN 14.4 ± 0.3 16.5 ± 3.6 1728 ± 85 97.7 
pdFI 14.2 ± 0.2 15.2 ± 2.5 1681 ± 47 98.1 
'pdFI-pdFN 12.5 ± 0.6 23.5 ± 6.8 1237 ± 141 93.5 
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We also employed DLS to monitor the interactions of FN with  and ’ FI subspecies in 
a buffer containing 50 mM Tris, 1.1 mM CaCl2, 0.6 mM MgCl2, and 150 mM NaCl. Results are 
displayed in Figure 3.8 and Table 3.4. FN exhibited a polydisperse distribution with a smaller 
hydrodynamic radius of 10.3 ± 0.3 nm. On the other hand, both  and ’ FI subspecies showed 
a polydispersity distribution and larger hydrodynamic radius, 16.2 ± 0.5 nm and 17.1 ± 0.4 nm 
respectively, than the FN. The native complex appeared less polydisperse molecules than when 
analyzed in 100 mM NaCl and harsh conditions of 1 M NaCl and 6 M urea. The average 
hydrodynamic radius was 12.1 ± 0.2 nm, similar to the value obtained in 6 M Urea. The change 
in size distribution could be due to the presence of the calcium and magnesium in the buffer. 
 Interestingly, the addition of FN to  and ’ FI decreased the hydrodynamic radius of 
both FI species. An equimolar mixture of pdFN and pFI showed an average hydrodynamic 
radius of 13.7 ± 0.9 nm and polydispersity distribution similar to that of free pdFI. An 
equimolar mixture of pdFN and ’pdFI displayed an average hydrodynamic radius of 13.0 ± 0.4 
nm and polydispersity distribution similar to that of free ’pdFI. These results indicate that FN 
interacts with both  and ’. The reductions in hydrodynamic radius of both mixtures suggest 
that the two molecules are interacting to create a more compact product. This can be visualized 
as the more linear FI molecules folding around the globular FN. 
The hydrodynamic radius of ’pdFI-pdFN complex is similar to the published value for 
FI. At physiological pH and ionic strength of 0.15 M, the hydrodynamic radius of FI was 12.7 
nm [10]. However, the values obtained for pdFI and ’pdFI are much higher. 
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Figure 3.8 Size distributions of pdFN, pdFI, ’pdFI,  ’pdFI-pdFN complex, and 
mixtures of pdFN with pdFI and ’pdFI.  Measurements were performed by DLS at 25 ̊C 
in 150 mM NaCl tris-buffered solution containing physiological calcium and magnesium and pH 
7.4. 
 
Table 3.4 DLS parameters of pdFN, pdFI, ’pdFI, ’pdFI-pdFN complex, and mixtures 
of pdFN with pdFI and ’pdFI species analyzed in 150 mM NaCl.  
Item 
Hydrodynamic 
Radius  (nm) 
Polydispersity 
(%) 
Molecular 
weight estimate  
(kDa) 
Intensity 
distribution 
(%) 
pdFN 10.3 ±0.3 22.5 ± 2.2 786 ± 63 92.8 
pdFI 16.2 ± 0.5 28.4 ± 4.8 2268 ± 167 98.1 
'pdFI 17.1 ± 0.4 23 ± 1.3 2599 ± 145 97.1 
pdFI+pdFN 13.7 ± 0.9 29 ± 12.2 1541 ± 240 79.9 
'pdFI+pdFN 13.0 ±0.4 21.2 ± 1.6 1368 ± 99 83.4 
'pdFI-pdFN 12.1 ± 0.2 20.2 ± 2 1150 ± 54 99.5 
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Analytical Ultracentrifugation 
 
Sedimentation velocity 
 
The sedimentation coefficients of pdFN, ’pdFI, ’pdFI-pdFN complex, and an 
equimolar mixture of ’pdFI and pdFN were measured by sedimentation velocity experiment at 
35,000 rpm. In these experiments, the sedimentation coefficient distributions of the proteins were 
monitored. The sedimentation coefficients and frictional ratios were calculated from the fitted 
data. FN exhibited a single dominant peak with sedimentation coefficient of 13 S and molecular 
weight of 545 kDa (Figure 3.9). The calculated molecular value is higher than the value of 450 
kDa estimated from mobility in sodium dodcylsulfate gel electrophoresis. This difference in 
molecular weight value from our experiments may reflect ionic strength differences in the buffer. 
The S value is consistent with the established sedimentation constant of FN which is in the range 
12-14 S at physiological pH and salt [3, 12-14]. However, at higher pH and salt concentration, 
FN adopt an extended conformation that sediment at 6-8 S [3, 4, 15]. The frictional ratio was 
high, 1.85, a value that characteristic of the extended length of FN. This value falls within the 
reported 1.7 frictional coefficient of FN [16]. The ’pdFI showed a sharp dominant peak at 7.7 
S and molecular weight of 229 kDa less than the established molecular weight of FI (Figure 
3.10). A minor peak at 11.2 S with molecular weight of 402 kDa was also seen indicating the 
presence of some aggregate. The calculated frictional ratio was 1.8. The S(20, w) value is similar 
to the reported value of unfractionated plasma FI (7-8S) [17]. 
The native ’pdFI-pdFN complex exhibited two major peaks with characteristics similar 
to the individual FI and FN molecules (Figure 3.11).  The faster sedimenting peak has an S (20, 
w) value of 7.8 and molecular weight of 237 kDa, while the second peak had a higher 
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sedimentation coefficient of 13.7 S and molecular weight of 545 kDa. A faint peak trailing the 
first and leading the second major two peaks was seen with an S (20, w) value of 10.6 and 
molecular weight of 376 kDa. The overall frictional coefficient of the complex was 1.82. This 
agrees with Matsuda et al who showed that the FI and FN component of cryofibrinogen 
dissociated from each other when analyzed by ultracentrifugation in 300 mM NaCl solution at 
22-24 °C. Matsuda also showed that the FN from cryofibrinogen sedimented at 11.3 S and 12.8 S 
which are similar to the value we obtained. The sedimentation velocity profiles for equimolar 
mixtures of ’pdFI plus pdFN (Figure 3.12) and  pdFI plus pdFN (Figure 3.13) were very 
similar to that of the native complex. Both mixtures displayed peaks corresponding to the 
individuals FI and FN molecules. The frictional ratio of a mixture of ’pdFI plus pdFN was 
identical to that of ’pdFI and slightly larger than the frictional ratio of a mixture of pdFI plus 
pdFN.  Altogether, the sedimentation profiles of the plasma mixtures of fibronectin and 
fibrinogen subspecies appear to match the profile of the native complex. A component with a 
sedimentation coefficient beyond that of fibronectin was not observed in the sedimentation 
velocity experiments. 
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Figure 3.9 Sedimentation velocity data of pdFN.  A set of 250 scans were collected at 3.5 min 
intervals in a Beckman Coulter XL-1 analytical ultracentrifuge using the absorbance optical 
system. Samples were analyzed at 35,000 rpm and 20 °C in Tris/NaCl buffer, pH 7.5. 
 
Figure 3.10 Sedimentation velocity data of ’pdFI.  A set of 250 scans were collected at 3.5 
min intervals in a Beckman Coulter XL-1 analytical ultracentrifuge using the absorbance optical 
system. Analysis was performed at 35,000 rpm and 20 °C in Tris/NaCl buffer, pH 7.5. 
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Figure 3.11 Sedimentation velocity data of the isolated ’FI-FN complex.  A set of 250 
scans were collected at 3.5 min intervals in a Beckman Coulter XL-1 analytical ultracentrifuge 
using the absorbance optical system. Samples were analyzed at 35,000 rpm and 20 °C in 
Tris/NaCl buffer, pH 7.5. 
 
Figure 3.12 Sedimentation velocity data of an equimolar mixture of ’pdFI and pdFN.  A 
set of 250 scans were collected at 3.5 min intervals in a Beckman Coulter XL-1 analytical 
ultracentrifuge using the absorbance optical system. Data was collected at 35,000 rpm and 20 °C 
in Tris/NaCl buffer, pH 7.5. 
71 
 
 
 
 
Figure 3.13 Sedimentation velocity data of an equimolar mixture of pdFI and pdFN.  A 
set of 250 scans were collected at 3.5 min intervals in a Beckman Coulter XL-1 analytical 
ultracentrifuge using the absorbance optical system. Data was collected at 35,000 rpm and 20 °C 
in Tris/NaCl buffer, pH 7.5. 
Sedimentation Equilibrium 
 
Sedimentation equilibrium data of pdFI, pdFN, ’pdFI-pdFN, and a mixture of ’pdFI 
and pdFN were collected at different rotor speeds (3000 to 8000 rpm) and fitted to the single 
ideal species model. Fitting the data to a self-association model did not improve the fitting or 
change the molecular weight estimates and thus was not used. The results of sedimentation 
equilibrium experiments are presented in Figures 3.14 through 3.17 which show the 
concentration gradients obtained during sedimentation equilibrium at four different rotor speeds. 
The combined data of unfractionated pdFI collected at 4000, 6000, and 8000 rpm fit to a 
molecular weight of 342.1 ± 11.6 kDa (Figure 3.14), which is similar to the reported molecular 
weight of pdFI (340 kDa). The residuals are distributed randomly and tightly about the fit, 
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indicating that the single ideal species model describes the data well. FN fit returned a molecular 
weight of 494.9 ± 29.5 (Figure 3.15), which is within the calculated molecular weight for FN 
(450 kDa). The residuals are randomly distributed in all data sets, indicating that the self-
association model can describe the reaction independent of the rotor speed and initial protein 
concentration. 
Fitting the combined data of the native complex at 3000 and 6000 rpm returned a 
molecular weight of 645.8 ± 36.2 kDa (Figure 3.16), which is lower than the expected 790 kDa 
molecular weight of the complex. Residuals are randomly distributed around zero, indicating the 
single ideal species model is a good description of the data. The combined data for a mixture of 
’pdFI and pdFN fit to a molecular weight of 288.6 ± 14.7 kDa (Figure 3.17). There is no 
established molecular weight for a mixture of ’pdFI and pdFN or pdFI and pdFN to compare 
to. Residuals are randomly distributed around zero.   
 
 
 
 
 
 
 
Figure 3.14 Sedimentation equilibrium data of unfractionated pdFI. Protein samples were 
centrifuged for 22 h at 4000 (solid circles), 6000 (open circles) and 8000 (triangles) rpm at 20 
°C. The solid line through the points is the weighted nonlinear least-squares fit to an ideal single-
species model. Molecular weight (kDa) estimate of 342.1 (± 11.6) for pdFI was generated from 
the fitting analysis. The residuals of each fit speed (4000 rpm, solid circles; 6000 rpm, open 
circles; 8000 rpm, triangles) are displayed in the bottom.  
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Figure 3.15 Sedimentation equilibrium data of pdFN.  Protein samples were centrifuged for 
22 h at 3000 and 6000 rpm at 20 °C. Shown is the combined fitting of data collected at 3000 and 
6000 rpm. The solid line through the points is the weighted nonlinear least-squares fit to an ideal 
single-species model. Molecular weight (kDa) estimate of 494.9 (± 29.5) for pdFN was 
generated from the fitting analysis. The residual for the best-fit analysis at each speed is shown 
above.  
 
 
 
 
 
 
 
 
Figure 3.16 Sedimentation equilibrium data of ’pdFI-pdFN. Protein samples were 
centrifuged for 22 h at 3000 and 6000 rpm at 20 °C. Shown is the combined fitting of data 
collected at 3000 and 6000 rpm. The solid line through the points is the weighted nonlinear least-
squares fit to an ideal single-species model. Molecular weight (kDa) estimate of 645.8 (± 36.2) 
for ’pdFI-pdFN was generated from the fitting analysis. The residual for the best-fit analysis at 
each speed is shown above.  
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Figure 3.17 Sedimentation equilibrium data of a mixture of ’pdFI and pdFN.  Protein 
samples were centrifuged for 22 h at 3000 and 6000 rpm at 20 °C. Shown is the combined fitting 
of data collected at 3000 and 6000 rpm. The solid line through the points is the weighted 
nonlinear least-squares fit to an ideal single-species model. Molecular weight (kDa) estimate of 
288.6 (± 14.7) for ’pdFI+ pdFN was generated from the fitting analysis. The residual for the 
best-fit analysis at each speed is shown above.  
 
Discussions 
 
When analyzed on SEC at room temperature, the complex did not dissociate to form 
individual FI and FN providing further evidence for a room-temperature stable ’pdFI-pdFN 
complex. This in contrast to the complex obtained from pathological plasma by heparin at near-
freezing temperature which tends to dissociate at room temperature. SEC also demonstrated that 
the complex is a compact structure at 200 mM NaCl and pH 7.0. We attempted to reconstitute 
the complex using mixtures of FN plus FI and FN plus ’pdFI. SEC indicated that a mixture 
of FN with an excess molar of ’pdFI exhibited characteristics similar to the isolated complex.  
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DLS measurements of the size and mass distribution of the native complex were 
performed under physiologic, high and low ionic strength, and denaturing conditions and 
compared to measurements of individual pdFN,  and ’ pdFI species. Results showed that the 
hydrodynamic radius of the complex increased when analyzed in 1 M NaCl compared to the low 
ionic strength of 100 mM NaCl. When a denaturing condition of 6 M urea is used, the complex 
exhibited a much larger hydrodynamic radius. This corroborates the SEC results that the 
complex is a more compact structure at low ionic strength condition but unfold into the linear 
conformation under harsh condition in a manner similar to free FN. This agrees with Nagamatsu 
at el results that showed the complex as a more compact structure at low ionic strength. The 
conformation of the complex was dependent on solvent conditions as that of free FN. 
These findings agree with the physicochemical studies that showed FN structure is highly 
flexible and depends on the solution conditions. It is known that FN assumes a more compact 
structure at near physiological condition but undergo a conformational change to the extended 
form under high salt and chaotropic conditions. Studies have demonstrated that under a 
denaturing condition of 8 M urea, FN unfolds into a linear polymer with a radius of gyration of 
30 nm [11]. FN flexibility is also apparent from SEM studies that showed the molecule in 
different shapes that ranged from a compact structure, elongated, and rod-like structure.  
Based on the DLS and SEC results, we assume that the compact structure of the complex 
results from the complete or partial folding of the linear FI around the more compact FN. The 
proposed structure is schematically depicted in Figure 3.18. This hypothesis is supported by the 
observation that FN exists in a compact conformation at physiological pH and ionic strength. 
Rotary shadowing electron microscopy showed that FN in the compact conformation appeared 
more bent and folded upon itself [15]. Electron microscopy revealed that FN molecules are more 
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strongly curved or bent to generate an irregularly coiled compact structure in low ionic strength, 
the strand bent. These observations support the hypothesis that at low ionic strength, FN curved, 
or folded back on itself to form a more compact structure. A possible explanation is that the 
oppositely charged parts of FN molecules interact electrostatically causing the extended strand to 
fold into a compact structure [18]. Another possible explanation is that folding is generated by 
short range electrostatic interactions at many points along the strand. At high ionic strength FN 
exists as extended strands.   
The binding sites involved in the crosslinking of FN to fibrinogen or fibrin are localized 
in the NH- terminal region of the FN molecule and the COOH-terminal region of the FI α-chains 
[19-21] . This indicates that both  and ’ FI variants interact with FN through their α-chains. 
It’s known that the ’FI is longer and contains more anionic groups than FI [22]. This enables 
’FI to fold more tightly around the FN molecule than FI. 
 
Figure 3.18 schematic diagram of  and ’ interactions with FN. 
Fibronectin 
Fibrinogen γ γ 
Fibrinogen γ γ’ γ’ 
Fibronectin 
Fibronectin 
Fibrinogen γ γ’ 
Fibrinogen γ γ 
γ’ γ’ 
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Chapter 4 Characterize the kinetics and viscoelastic properties of the isolated 
’pdFI-pdFN complex and comparable mixtures of FI and FN 
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Abstract  
 
Clottability of the native γγ’pdFI-pdFN complex was evaluated by Thromboelastography 
(TEG) assay. Clots derived from the native complex had appreciably enhanced clot strength than 
any other species. The effect of fibronectin on the polymerization rate and viscoelastic properties 
of fibrin clots made from unfractionated FI and fractionated  and ’ subspecies was also 
evaluated by TEG. Results showed that FN in the concentration range 0.5-4.5 mg/ml did not 
perturb polymerization rates and gelation of clots. The clot initiation and propagation time was 
not influenced by the presence of FN. The initiation and propagation of  and ’ FI clots were 
inhibited in the absence of FXIII. Interestingly, the addition of FN without crosslinking restored 
the initiation and propagation time of these clots. 
  FN, even at the near physiological level of concentration, has shown effect on the rigidity 
of fibrin clots. Results showed an increase in the maximal amplitude and shear elastic modulus 
of clots made from unfractionated FI and ’FI as a function of supplementing with measured 
doses of the purified FN (0.5-4.5 mg/ml). FN had dual effect on the rigidity of clots from plasma 
and recombinant FI. While lower level of FN (0.5 and 2 mg/ml) decreased the shear modulus 
and maximal amplitude of FI clots, higher level of FN (3 and 4.5 mg/ml) increased the 
modulus and maximal amplitude. Even without rFXIIIa mediated crosslinking, FN improved the 
shear modulus of both  and ’ FI clots. 
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Introduction  
 
It’s well established that FN is covalently incorporated into fibrin clots by activated 
FXIII. The influence of FN when present on the polymerization and gel structure of fibrin clots 
is not well resolved. For example, Kamykowski and colleagues  [1] measured the effect of FN on 
shear moduli and creep compliances of fine clots with little lateral aggregation of the fibrin 
protofibrils and coarse clots with substantial lateral aggregation of the fibrin protofibrils. They 
found that FN crosslinked to fine clots decreased the shear modulus of clots whereas the addition 
of FN with or without crosslinking to coarse clots increased the rate and final magnitude of shear 
modulus. The authors believed that the formation of alpha-fibronectin bonds increased the 
binding of protofibrils together and stiffened the protofibrils bundles leading to increase in the 
shear modulus. In contrast to Kamykowski’s finding, Chow reported that pdFN had little impact 
on the mechanical properties of fibrin clots derived from platelet free plasma (PFP) and platelet 
rich plasma (PRP) [2]. 
The effect of FN on the polymerization of fibrin was also investigated by using liquid 
permeation of gels formed in the present of FN [3]. This approach provided information on the 
size, shape, and orientation of the gel pores associated with FN incorporation. The results 
indicated that the rate of activation and polymerization of FI is not affected by the presence of 
FN. The covalent incorporation of FN, however, increased the turbidity of the fibrin gel and 
significantly reduced the permeability coefficient.  The authors concluded that increase in 
turbidity indicates increase in the thickness of the fibrin strands while decrease in permeability 
was due to increase in width of the strands. In separate studies, Niewiarowsk and Cierniewski 
reported that FN inhibited formation of blood clots by influencing the polymerization process 
and decreasing thrombin clotting time [4]. Using turbidity measurement, the addition of FN to FI 
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at a molar ratio of 1:5 inhibited the early phase of polymerization leading to prolongation of the 
lag period. The polymerization processes was completely inhibited when the molar concentration 
of FN to FI was increased to 1:2. It was speculated that the inhibitory effect of FN is due to the 
steric hindrance of either thrombin peptide bonds or the polymerization sites in FI. Other studies 
have demonstrated that FN inhibits fibrin polymerization by maintaining fibrin monomers 
solubility and re-solubilize fibrin at 37 C. The authors presumed that such solubilization permit 
fibrin to move in the circulation until it is cleared [5].   
Measuring the rheology of fibrin clots  
 
Various techniques were developed to measure the tensile strength and shear strength of 
clots derived from fibrin sealants formulations. Most of these methods attempt to detect a liquid-
to-solid transition during coagulation. These techniques include TEG, shear viscosity 
measurements, and complex shear modulus measurements such as controlled stress and 
controlled strain rheometers. Photometric methods such as turbidimetry are also used to measure 
clot’s physical properties. For instance, Chow employed Rheometrics Fluid rheometer to study 
the effect of FN on clotting of PFP and PRP [6]. The device measures the rheological properties 
of fluids using either steady shear or dynamic testing modes. Studies by Kamykowski were 
conducted on a Plazek torsional creep and recovery apparatus in which disk-shaped clot is 
deformed in torsion. Many of these techniques provide little information on the kinetics of the 
clot formation. We employed TEG to evaluate the effect of FN on the shear elastic modulus and 
kinetics of clot formation.  
The TEG, developed by Hartert in 1948, is a coaxial cylinder rheometer that measures the 
growth of elasticity during clot formation. The instrument measures elasticity by monitoring the 
82 
 
motion of the inner cylinder (pin) suspended on a torsion wire, when the outer cylinder (cup) is 
oscillated back and forth [7]. TEG measure continuously the evolution of viscoelasticity during 
the course of fibrin polymerization. The adherence of the clot in the cup ensures that retraction is 
negligible. The TEG was shown to provide reliable, reproducible information on the rheology of 
clots from fibrin sealant preparations. Herring and colleagues have demonstrated that TEG can 
be used as a simple, rapid, and reproducible technique for evaluating the mechanical properties 
of clots derived from different fibrin sealant preparation [8]. Compared to other techniques, the 
TEG can provide kinetic data on the rheology of fibrin clot formation. It can provide a real-time 
determination of the onset of clot formation, the rate of clot formation, maximum clot strength, 
and degradation of the clots.   
Shear elastic modulus measurements were done on a TEG 5000 Thromboelastograph 
Hemostasis Analyzer System. The instrument consisted of a temperature-controlled chamber 
with two independent measuring channels. Each channel contained a cup and a pin suspended on 
a torsion wire. To measure the shear elastic modulus, clotting factors are placed in TEG cup and 
a pin suspended in a torsion wire is lowered into the sample. The cuvette rotates slowly back and 
forth around its vertical axis through very small angle of 4̊ 45’. The rotation of the cuvette takes 
3.5 sec for one direction then comes to standstill for 1 sec and moves back in the other direction 
for 3.5 sec. Clotting factors transmit little or no torque from cup to pin. As clot develops, fibrin 
fibers fill the gap between the cup and pin coupling the motion of the cup and the pin. This 
coupling is directly proportional to the clot strength. The movement of the torsion wire is 
converted by an electrical-mechanical transducer into electrical signal which then amplified and 
recorded on computer. Data analysis is done using the TEG analytical software which 
automatically and independently calculates the TEG parameters. Pin movement in both the 
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clockwise and counterclockwise directions is simultaneously recorded and plotted in the 
computer as separate peaks (Figure 4.1). Five parameters are recorded: 
 The reaction time (R or r) is the time needed to initiate clot formation and measured as 
the time or distance from the start of the reaction to the point of first significant clot 
formation with an amplitude of 2 mm. 
 The coagulation or propagation time (K) is the time or distance taken to generate a clot 
with amplitude of 20 mm. It indicates the rate of increase of elastic modulus in the 
sample or how fast the clot structure is forming. 
 The angle (α) reflects the kinetics of clot formation and measured between the midline of 
the tracing and a line drawn from the 1 mm wide point tangential to the curve. 
 The maximum amplitude (MA) is the width of the curve at its widest point. It shows the 
maximum clot elastic shear modulus attainable. 
 The shear elastic modulus (G) is measured in dynes/cm2 
The absolute elastic shear modulus can be estimated from thromboelastograph amplitude as 
follows: 
𝐺 =  
(5000𝐴)
(100 − 𝐴)
 
Where G is the elastic shear modulus in dynes/cm
2 
and A is the width of the tracing in 
millimeters. 
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Figure 4.1 TEG tracing parameters 
 
In this section, the effect of FN on the clotting of FI was investigated with the aid of 
TEG. The role of FN was studied by comparing the kinetic parameters and the dynamic elastic 
shear modulus of plasma and recombinant unfractionated FI, FI, and ’FI samples with and 
without FN. 
Materials and Methods 
 
Materials 
 
All reagents of highest purity were purchased from Sigma Chemical Company (St. Louis, MO) 
unless otherwise noted. Human plasma fibrinogen depleted of fibronectin, plasminogen, and von 
Willebrand Factor was purchased from Enzyme Research Laboratories (South Bend, IN). 
Fibrinogen and fibronectin were purified from pool of human plasma donated by the U.S. Army 
Materials Command (Fort Detrick, MD). Human fibrinogen was purified from plasma by 
cryoprecipitation followed by two ethanol precipitation as previously described. Human 
fibronectin was isolated from plasma on Gelatin Sepharose as previously described. 
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Recombinant fibrinogen (rFI), expressed in the milk of transgenic cows, was kindly supplied by 
Nick Masiello (LFB). Recombinant human thrombin (rFIIa) was purchased from The Medicines 
Company (Parsippany, NJ). Recombinant human FXIII (rFXIIIa), expressed in Pichia Pastoris, 
was purified on His-Bind Resin (Novagen, CA). TEG disposable cups and pins were bought 
from Haemoscope (Niles, IL). 
Evaluating Clottability of FI-FN complex by Thromboelastography 
 
The clotting kinetics of purified ’pdFI-pdFN complex was evaluated by TEG 
Hemostasis system 5000 series (Haemoscope Corporation, Niles, IL). Samples of ’pdFI-pdFN 
complex or pdFI (final concentrations of 9 mg/ml) were placed in a TEG cup, which is kept at 
37
o
C by the instrument. rFXIIIa (final concentration of 0.36 mg/ml), CaCl2 solution (final 
concentration of 12 mM) and Ringer’s solution (155 mM NaCl, 5 mM KCl, 2 mM CaCl2, and 1 
mM MgCl2) were added followed immediately by rFIIa (final concentration of 105.6 U/ml) to 
trigger clot formation. The TEG analyzer collected clot parameters such as the time to reach 2 
mm clot strength (R), the time to reach 20 mm clot strength (K), and the maximum clot strength 
(MA) every five seconds for 30 minutes. The data was collected and analyzed in Microsoft 
Excel. 
Effect of FN on the clottability of FI 
 
 The effect of FN on the kinetics and mechanical properties of fibrin clots was also 
evaluated by TEG Hemostasis system 5000 series. FN effect was measured for both plasma 
derived and recombinant unfractionated FI and fractionated and’ FI subspecies that were 
isolated on DEAE Sepharose as previously described. Dose response curves were created by 
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holding the concentration of FI constant (4.5 mg/ml) while varying the level of FN (0.5, 2, 3, and 
4.5 mg/ml). 
Statistical analysis 
 
Data of repeated experiments were expressed as mean and standard deviation. 
Differences in the maximal amplitude and shear modulus were analyzed by one-way ANOVA 
analysis using the software GraphPad Prims, version 5.0 (GraphPad Software, San Diego, CA). P 
values lower than 0.05 were considered to be significant. 
Results 
 
Clottability of ’pdFI-pdFN complex by Thromboelastography 
 
The kinetics and mechanical properties of ’pdFI-pdFN clots were measured by TEG 
and compared to the properties of clots derived from plasma FI. Results are shown in Figure 4.2 
and Table 4.1. Both types of clots showed very similar clotting kinetics as evident by the clot 
initiation time (R) and propagation time (K). The formation of both types of clots was initiated 
10 seconds after rFIIa was added to the complex and FI. The clot propagation time was also 
identical, both types of clots needed 50 seconds to reach 20 mm amplitude. However, clots made 
from ’pdFI-pdFN showed superior mechanical properties than pdFI clots. The maximum 
amplitude (MA) of ’pdFI-pdFN clots (79.93 ± 1.37 mm) was 13% higher than the maximum 
amplitude of pdFI clots (70.57 ± 1.89 mm). In addition, the shear elastic modulus strength (G) of 
’pdFI-pdFN clots (20004.30 ± 1790 dynes/sec) was 60% stronger than that of pdFI (12048.20 
± 1062.45 dynes/sec). This result is significant considering that the TEG measurements were 
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performed at a concentration of 9 mg/ml for both samples but the pdFI content of the complex 
was ~50% of the commercially purified pdFI (Enzyme Research Laboratories).  
Figure 4.2 Thromboelastography analysis of clots formed from pdFI and native ’pdFI-
pdFN complex.  Viscoelastic and kinetic parameters were measured by TEG Hemostasis system 
5000 series. Clotting mixtures included pdFI (9 mg/ml), pdFI-pdFN complex (9 mg/ml), rFXIIIa 
(0.36 mg/ml), rFIIa (105.6 U/ml), CaCl2 (12 mM), and Ringer’s solution. 
 
Table 4.1 Kinetics and viscoelastic parameters of clots from pdFI and ’pdFI-pdFN 
complex. 
Type of clot R (sec) K (sec) 
Angle 
(deg) 
MA 
(mm) 
G 
(dynes/sec) 
Unfractionated pdFI  10.00 50.00 85.80 70.57 12048.20 
pdFI-pdFN Complex 10.00 50.00 86.93 79.93 20004.30 
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The effect of FN on the clotting of unfractionated pdFI 
 
The impact of pdFN on viscoelastic and kinetic parameters of clot developed by normal 
unfractionated pdFI containing ~80%  and 15% ’ subspecies was evaluated by TEG assay. 
The study was conducted using commercially available pdFI (Enzyme Research Laboratories) 
that has been depleted of FN. Measurements were made by holding pdFI concentration constant 
(4.5 mg/ml) while dosing pdFN ( 2 and 4.5 mg/ml). Results are displayed in Figure 4.3. TEG 
parameters R, K, Angle, MA, and G are presented in Table 4.2. As expected, FN alone 
demonstrated no clot formation or any sign of viscoelastic properties as evident by the flat line. 
As shown in the table, the addition of FN had no effect on the kinetics of pdFI clots. The time to 
clot initiation as determined by R is identical (10 seconds) for clots made with and without FN. 
The propagation time as determined by K is also identical (50 seconds) for both clots. The 
inclusion of pdFN, however, increased the maximum amplitude and shear strength of the clots. 
The increase was proportional to the amount of FN added. A lower level of FN (2 mg/ml) 
increased the maximum amplitude by 7.8% and shear strength by 14.4% whereas a higher level 
of FN (4.5 mg/ml) elevated the maximum amplitude by 21.1% and shear strength by 44.2%. 
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Figure 4.3 Thromboelastography analysis of clots formed from unfractionated pdFI.  
Viscoelastic and kinetic parameters were measured by TEG Hemostasis system 5000 series. 
Clotting mixtures included pdFI (4.5 mg/ml), rFXIIIa (0.36 mg/ml), rFIIa (105.6 U/ml), CaCl2 
(12 mM), and Ringer’s solution. 
 
Table 4.2 Kinetics and Viscoelastic parameters of clots from unfractionated pdFI 
Type of clot R (sec) K (sec) Angle (deg) 
MA 
(mm) 
G 
(dynes/sec) 
pdFI (4.5 mg/ml) + pdFN (4.5 mg/ml) 10.00 50.00 84.70 52.60 5552.23 
pdFI (4.5 mg/ml) + pdFN (0.5 mg/ml) 10.00 50.00 84.10 49.18 4842.75 
pdFI (4.5 mg/ml) + pdFN (2 mg/ml) 10.00 50.00 83.77 46.83 4406.43 
pdFI (4.5 mg/ml) 10.00 50.00 83.83 43.45 3850.73 
 
 
The effect of FN on the clotting of  and ’ pdFI 
 
The effect of pdFN on the viscoelastic and mechanical properties of clots formed by 
’pdFI and pdFI was examined by TEG at 37 ̊C. The results are depicted in Figure 4.4 and 
Table 4.3. A dose response curve was generated by keeping the concentration of 
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pdFIor'pdFI constant while varying pdFN levels (0.5, 2, 3, and 4.5 mg/ml). The presence of 
FN did not influence the kinetic of ’pdFI clot formation. It took the same time (10 sec) to 
initiate clot formation after rFIIa was added to ’pdFI and a mixture of ’pdFI plus pdFN. 
Similarly, the time to reach 20 mm clot strength was the same (50 sec) for both types of clots. 
However, the presence of FN increased the shear modulus and maximal strength of clots in a 
manner that dependent on the amount of FN added. A low concentration of FN (0.5 mg/ml) 
increased the maximum amplitude by 4.9% and shear modulus by 10.3%, while a high level of 
FN (4.5 mg/ml) increased the maximum amplitude by 42.3% and shear modulus 146.6%. 
Increasing FN concentration from 2 to 3 mg/ml resulted in the largest increase in maximal 
amplitude (22.4%) and shear strength (88.4%). On the other hand, going from 3 to 4.5 mg/ml 
produced the smallest increase in maximal amplitude (3.5%) and shear strength (19.5%), 
suggesting a saturation level was attained. 
Similar to ’pdFI clots, FN did not affect the kinetic of pdFI clot formation (Figure 4.5 
and Table 4.4). Formation of clot in the presence or absence of FN was initiated 10 sec following 
the addition of rFIIa. Also, it took all clots 50 sec to reach 20 mm amplitude. The addition of FN, 
however, had a mixed effect on the maximum amplitude and shear modulus of pdFI clots. 
While lower levels of FN (0.5 and 2 mg/ml) decreased the shear modulus, higher levels (3 and 
4.5 mg/ml) increased the shear modulus. The inhibitory effect of FN on clot strength was 
maximal at FN concentration 0.5 mg/ml, which lowered maximum amplitude by 15% and shear 
modulus by 28%. FN at 4.5 mg/ml enhanced the maximum amplitude by 19.3% and shear 
modulus 55.4%.  
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Figure 4.4 Thromboelastography analysis of clots formed from mixtures of 'pdFI and 
pdFN. Viscoelastic and kinetic parameters were measured by TEG Hemostasis system 5000 
series. Clotting mixtures included pdFI (4.5 mg/ml), pdFN (0.5, 2, and 3 mg/ml), rFXIIIa (0.36 
mg/ml), rFIIa (105.6 U/ml), CaCl2 (12 mM), and Ringer’s solution. 
 
Table 4.3 Kinetics and viscoelastic parameters of clots from mixtures of ’pdFI and FN 
Type of clot R (sec) K (sec) 
Angle 
(deg) 
MA 
(mm) 
G 
(dynes/sec) 
gg'pdFI+pdFN (4.5+4.5 mg/ml) 10.00 50.00 86.40 71.03 12,322.93 
gg'pdFI+pdFN (4.5+3 mg/ml) 10.00 50.00 85.88 69.28 11,348.25 
gg'pdFI+pdFN (4.5+2 mg/ml) 10.00 50.00 85.37 58.07 6,928.63 
gg'pdFI+pdFN (4.5+0.5 mg/ml) 8.33 50.00 84.60 52.37 5,510.43 
gg'pdFI (4.5 mg/ml) 10.00 50.00 84.57 49.93 4,997.23 
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Figure 4.5 Thromboelastography analysis of clots formed from mixtures of pdFI and 
pdFN. Viscoelastic and kinetic parameters were measured by TEG Hemostasis system 5000 
series. Clotting mixtures included pdFI (4.5 mg/ml), pdFN (0.5, 2, and 3 mg/ml), rFXIIIa (0.36 
mg/ml), rFIIa (105.6 U/ml), CaCl2 (12 mM), and Ringer’s solution. 
 
Table 4.4 Kinetics and viscoelastic parameters of clots from mixtures of pdFI and FN 
Type of clot R (sec) K (sec) Angle (deg) MA (mm) G (dynes/sec) 
ggpdFI+pdFN (4.5+4.5 mg/ml) 10.00 50.00 86.27 65.20 9,418.67 
ggpdFI+pdFN (4.5+3 mg/ml) 10.00 50.00 85.50 57.05 6692.78 
ggpdFI (4.5 mg/ml) 10.00 50.00 85.50 54.67 6062.07 
ggpdFI+pdFN (4.5+2 mg/ml) 10.00 50.00 85.20 53.43 5764.37 
ggpdFI+pdFN (4.5+0.5 mg/ml) 10.00 50.00 84.43 46.47 4365.47 
 
The viscoelastic and mechanical properties of the native ’pdFI-pdFN complex and 
mixtures of ’pdFI plus pdFN and pdFI plus pdFN complex are shown in Figure 4.6 and 
Table 4.5. FN did not interfere with the clotting kinetics of native and reconstituted complex; 
time to clot initiation and propagation was similar for both the complex and the control  and ’ 
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FI. However, the addition of exogenous FN to ’pdFI and pdFI did not create clots with 
mechanical strength as those of native complex. The maximum amplitude of clots made from the 
native ’pdFI-pdFN complex was 7.1% and 14.3% greater than the amplitude of clots from a 
mixture of ’pdFI with pdFN and pdFI with pdFN, respectively. This shows that the 
viscoelastic properties of the native complex can only be partially duplicated using exogenous 
mixtures of ’pdFI and pdFN. 
We also examined the polymerization rate and gel structure of  and ’ FI variants by 
TEG. Results were averaged from several experiments. Figure 4.6 and Table 4.5 illustrate that 
there is no kinetic difference between ’pdFI and pdFI clots. However, the maximal amplitude 
attained by ’pdFI clots was 3.7% greater than the amplitude of pdFI clots. In addition, the 
shear strength of ’pdFI clots was 8.2% greater than the shear strength of pdFI clots. The 
higher shear strength of clots made from ’pdFI can be attributed to the FXIII mediated 
crosslinking of fibrin monomers.  It’s well established that fibrinogen ’ contains binding sites 
for FXIII and serve as a carrier for the transglutaminase in the circulation. Therefore, clots made 
from 'FI are more extensively cross-linked and resistant to proteolytic degradation than clots 
derived from pdFI.  ’ affects clot properties by concentrating and increasing the rate of FXIII 
activation at the site of vascular injury. It has been shown that the more extensively cross-linked 
’ fibrin clots are more resistant to clot lysis than . The higher rate of FXIII associated 
with ’ fibrinogen was thought to be responsible for the large increase in fibrinolysis resistance 
of ’ fibrin compared with  fibrin. 
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Figure 4.6 Thromboelastography comparison of clots formed from the native and 
reconstituted ’pdFI-pdFN complex.  Viscoelastic and kinetic parameters were measured by 
TEG Hemostasis system 5000 series. Clotting mixtures included ’pdFI (4.5 mg/ml), ’pdFI-
pdFN complex (4.5 or 9 mg/ml), ’pdFI (4.5 mg/ml) + pdFN (4.5 mg/ml). rFXIIIa (0.36 
mg/ml), rFIIa (105.6 U/ml), CaCl2 (12 mM), and Ringer’s solution. 
 
Table 4.5 Viscoelastic and kinetic parameters of clots from the native and reconstituted 
’pdFI-pdFN complex. 
Type of clot R (sec) K (sec) Angle (deg) MA (mm) 
G 
(dynes/sec) 
gg'pdFI-pdFN (9 mg/ml) 10.00 50.00 86.90 76.10 15,960.77 
gg'pdFI+pdFN (4.5+4.5 mg/ml) 10.00 50.00 86.40 71.03 12322.93 
ggpdFI+pdFN (4.5+4.5 mg/ml) 10.00 50.00 86.27 65.20 9418.67 
gg'pdFI-pdFN (4.5 mg/ml) 11.00 50.00 84.78 60.20 7571.34 
gg'pdFI (4.5 mg/ml) 10.00 50.00 85.07 57.75 6848.72 
ggpdFI (4.5 mg/ml) 10.00 50.0 82.43 55.7 6328.59 
 
 
 
95 
 
The effect of adding FN without crosslinking on the clotting of  and ’ 
 
We also examined the effect of adding FN without FXIII mediated crosslinking on the 
strength and kinetics of clots derived from  and ’ pdFI. Results are shown in Figure 4.7 and 
Table 4.6. It was found that in the absence of FXIIIa and FN, the propagation time of both  
(748.75 sec) and ’ (93.33 sec) clots were delayed. The clot initiation time of the  clots were 
also delayed (18.75 sec). However, the inclusion of FN restored the initiation and propagation 
time of both types of clots to the values of samples containing FXIIIa. 
Even without FXIII mediated crosslinking, the addition of FN increased the maximal 
strength and shear modulus of both  and ’ FI clots. FN increased the maximal strength of 
pdFI clots by 60.6% and ’pdFI clots by 19%. The increase in shear strength was 94.7% for 
pdFI clots and 26.3% for ’pdFI clots. This contrast the finding that, without crosslinking by 
FXIII, FI clots were 2.7 times stiffer than ’ [10]. However, the maximal amplitude and shear 
strength of unligated clots from a mixture of pdFI plus pdFN clots was 1.59 and 5.53 times 
lower than the crosslinked pdFI clots. Likewise, the maximal amplitude and shear strength of 
unligated clots from a mixture of ’pdFI plus pdFN was 0.77 and 2.24 times lower compared to 
the ligated ’pdFI clots. This shows that the difference in clot strength is due to the FXIIIa 
mediated covalent crosslinking of FN. It’s well established that FXIIIa catalyze the formation of 
 and α dimers between adjacent fibrin strands. FXIIIa also covalently crosslinks FN to fibrin by 
catalyzing the formation of bonds between Lys residue in the C-terminal of the fibrin α-chain 
and Gln receptor residues in the N-terminal of FN [11]. The formation of additional fibrin-FN 
was thought to contribute to clot strength. 
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Figure 4.7 Thromboelastography analysis of clots formed from  and ’pdFI with or 
without FXIII and pdFN.  Viscoelastic and kinetic parameters were measured by TEG 
Hemostasis system 5000 series. Clotting mixtures included pdFI (4.5 mg/ml), ’pdFI (4.5 
mg/ml), pdFN (4.5 mg/ml). rFXIIIa (0.36 mg/ml), rFIIa (105.6 U/ml), CaCl2 (12 mM), and 
Ringer’s solution. 
 
Table 4.6 Kinetics and viscoelastic parameters of clots from  and ’pdFI with or without 
FXIII and pdFN 
Type of clot R (sec) K (sec) 
Angle 
(deg) 
MA 
(mm) 
G 
(dynes/sec) 
gg'pdFI  + pdFN (4.5 + 4.5 mg/ml) 10.00 50.00 86.4 71.033 12,322.93 
ggpdFI + pdFN (4.5 + 4.5 mg/ml) 10.00 50.00 86.27 65.20 9,418.67 
ggpdFI + pdFN (4.5 + 4.5 mg/ml) No FXIIIa 10.00 50.00 83.67 36.73 2,902.57 
gg'pdFI + pdFN (4.5 + 4.5 mg/ml) No FXIIIa 10.00 50.00 82.00 27.38 1,885.95 
gg'pdFI (4.5 mg/ml) No FXIIIa 10.00 93.33 79.30 23.00 1,493.00 
ggpdFI (4.5 mg/ml) No FXIIIa 18.75 748.75 66.80 22.88 1,490.43 
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The effect of FN on the clotting of  and ’ rFI 
 
The effect of FN on the clotting of  and ’ rFI was also investigated by TEG at 37. The 
results are shown in Figures 4.8 and 4.9. TEG parameters are displayed in Tables 4.7 and 4.8. FN 
showed no inhibitory effect on the initiation and propagation of both  and ’ rFI clots. In fact, 
FN improved the propagation of ’rFI clots. FN, however, had mixed effect on the viscoelastic 
properties of ’rFI clots. While FN concentration 2 and 3 mg/ml slightly increased the maximal 
amplitude and shear strength, 0.5 mg/ml concentration appears to weaken the amplitude and 
strength of ’rFI clots. FN concentration 4.5 mg/ml enhanced the maximal amplitude by 24.2% 
and shear strength by 38.5%. FN also had dual effect on the maximal amplitude and shear 
strength of  rFI clots. While FN concentrations 0.5 and 2 mg/ml retarded maximal amplitude 
and shear strength, FN concentrations 3 and 4.5 mg/ml improved the amplitude and shear 
strength of  rFI clots. Figure 4.10 compares the impact of FN on the shear strength of clots 
developed from plasma and recombinant unfractionated FI and fractionated  and ’FI variant. 
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Figure 4.8 Thromboelastography analysis of clots formed from mixtures of 'rFI and 
pdFN.  Viscoelastic and kinetic parameters were measured by TEG Hemostasis system 5000 
series. Clotting mixtures included pdFI (4.5 mg/ml), pdFN (0.5, 2, and 3 mg/ml), rFXIIIa (0.36 
mg/ml), rFIIa (105.6 U/ml), CaCl2 (12 mM), and Ringer’s solution. 
 
Table 4.7 Kinetics and viscoelastic parameters of clots from mixtures of ’rFI and FN 
Type of clot R (sec) K (sec) 
Angle 
(deg) 
MA 
(mm) 
G 
(dynes/sec) 
gg'rFI+pdFN (4.5+4.5 mg/ml) 10.00 50.00 82.33 37.78 3042.85 
gg'rFI+pdFN (4.5+3 mg/ml) 10.00 50.00 80.57 30.90 2237.23 
gg'rFI+pdFN (4.5+2 mg/ml) 10.00 56.67 80.33 32.10 2373.73 
gg'rFI+pdFN (4.5+0.5 mg/ml) 10.00 71.67 79.07 29.97 2143.03 
gg'rFI (4.5 mg/ml) 10.00 72.00 79.52 30.42 2196.30 
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Figure 4.9 Thromboelastography analysis of clots formed from mixtures of rFI and 
pdFN.  Viscoelastic and kinetic parameters were measured by TEG Hemostasis system 5000 
series. Clotting mixtures included pdFI (4.5 mg/ml), pdFN (0.5, 2, and 3 mg/ml), rFXIIIa (0.36 
mg/ml), rFIIa (105.6 U/ml), CaCl2 (12 mM), and Ringer’s solution. 
 
Table 4.8 Kinetics and viscoelastic parameters of clots from mixtures of rFI and FN 
Type of clot R (sec) K (sec) 
Angle 
(deg) 
MA 
(mm) 
G 
(dynes/sec) 
ggrFI+pdFN (4.5+4.5 mg/ml) 10.00 50.00 83.17 40.17 3360.83 
ggrFI+pdFN (4.5+3 mg/ml) 10.00 50.00 81.30 35.47 2752.60 
ggrFI+pdFN (4.5+2 mg/ml) 10.00 51.67 81.00 32.87 2453.67 
ggrFI+pdFN (4.5+0.5 mg/ml) 10.00 68.33 79.13 32.40 2397.80 
ggrFI (4.5 mg/ml) 10.00 63.33 79.30 35.37 2733.87 
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Figure 4.10 Effect of FN on the shear modulus of clots made from unfractionated FI and 
fractionated  and ’ FI as determined by TEG. 
 
Discussion  
 
The viscoelastic properties of a fibrin clot are essential for its functions and will 
determine how it responds to the mechanical challenge created by the following blood. The clot 
must be strong enough to stem the flow of blood and elastic enough to withstand the shear forces 
generated by the flowing blood. Fibrin clot is a viscoelastic polymer with both viscous and 
elastic components [12]. The viscoelasticity determines how the clot responds to the forces 
created by the flowing blood. It has been shown that the inclusion of other proteins from plasma 
greatly influenced the mechanical properties of fibrin clots [13]. Studies have shown that fibrin 
clots made from plasma possess different properties than those created from purified proteins 
[14-16]. Clots formed in vivo can be different in certain conditions where some other proteins 
may be present in different quantities and under different conditions and thereby may be 
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responsible for modulating clot structure.  Since FN is the second largest component of the clot, 
4% of the total weight of the clot, measuring the effect of FN on clot’s properties is essential.  
The influence of FN on the kinetics and rigidity of various types of fibrin clots was 
assessed by TEG assay. Results showed that pdFN in the concentration range 0.5-4.5 mg/ml had 
no influence on the kinetics of clot formation of different FI containing species. FN, however, 
had a greater influence on the rigidity of fibrin clots. FN enhanced the maximal amplitude and 
shear elastic modulus of clots made from unfractionated plasma FI, plasma and recombinant 
’FI subspecies. FN had dual effect on the rigidity of plasma and recombinant FI. While FN 
concentration 0.5-2 mg/ml decreased the shear modulus and maximal amplitude of FI clots, 
FN concentration 3-4.5 mg/ml increased the modulus and maximal amplitude. 
Exogenous FN increased the rigidity of FI, and ’FI clots even in the absence of FXIII 
mediated crosslinking. However, the increase in strength of clots containing FN without FXIII 
mediated crosslinking is significantly lower than the strength of crosslinked clots. With ligation, 
FN improved the shear modulus of pdFI by a factor of 1.6 and ’pdFI by a factor of 2.5. 
Without ligation, the improvement was by a factor of 1.9 for pdFI and by a factor of 1.3 for 
’pdFI.  
The results presented here show that the native ’pdFI-pFN complex formed clots with 
viscoelastic properties that higher than any other species. The mechanical properties of the native 
complex clots can be partially duplicated with mixture of ’pdFI and FN, which formed clots 
with shear strength that 22.8% lower than the strength of the native complex clot. The higher 
stiffness displayed by clots from the native ’pdFI-pdFN complex and a mixture of ’pdFI plus 
pdFN can be attributed to the ’ crosslinking. This is consistent with previous functional studies 
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that showed that fibrin clot containing ’ species are more far cross-linked by FXIIIa than fibrin 
clot containing  Furthermore, clot lysis experiments demonstrated that fibrin derived from 
’pdFI has greater resistance to fibrinolysis [9]. Another possible explanation is that the 
interaction of FN with ’ result in the formational of multiple FN-’ bonds. We have shown 
that the native complex contains exclusively ’FI subspecies in a 1:1 mixture with FN. 
The augmentation of clot rigidity by plasma fibronectin is in agreement with the finding 
of Kamykowski et al that shown, depending on the ionic strength and the pH during 
polymerization, FN either increase or decrease the shear modulus of clot. FN has decreased the 
elastic modulus of fine clots formed at high ionic strength and pH and increased the modulus of 
coarse clots formed at physiological ionic strength and neutral pH.  FN enhanced the shear 
modulus of coarse clots by a factor of 2.0 without crosslinking and by a factor 2.4 with 
crosslinking. The enhancement was explained by the formation of additional FN-α bonds that 
stiffen protofibrils by binding them together. Our clots were formed at physiologic pH and ionic 
strength conditions that favors the generation of coarse clots. Our results contrasts the finding of 
Chow et al who reported that pdFN had little impact on the mechanical properties of fibrin clots 
derived from platelet free plasma and platelet rich plasma.  
Okada et al found that the presence of FN did not affect the clotting time or the initial rate 
of increase in turbidity which corresponds to the clot propagation time [3]. FN did not affect the 
clotting time nor the release of fibrinopeptides and consequently had no influence on the 
polymerization and gelation of fibrinogen. Incorporated FN, however, increased the turbidity and 
slightly decreased the permeability coefficient.  The authors conclude that FN increases the 
width of the strands and proposed a model in which FN diffuse through the loosely assembled 
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fibrin strands resulting in a sandwich-like arrangement of fibrin polymers separated by an array 
of FN molecules. This gel structures is expected to become much stronger than the structure 
stabilized solely by g and α crosslinks within the polymers of the strand. Our studies are in 
support of this conclusion. Separate studies by Niewiarowska and Cierniewski et al have 
revealed that FN inhibited fibrin formation by delaying the early phase of fibrin formation and 
decreasing the thrombin clotting time. In contrary, our studies showed that FN had no influence 
on the initiation of fibrin formation and propagation of the clot. In fact, FN speeds up clot 
development in some instances. 
The increased shear modulus of clots derived from ’ is likely due to the presence of 
FXIII. Biochemical studies have shown that the ’ chain of FI contains binding sites for FXIII 
and FII and also serves as a carrier for FXIII in the circulation. Therefore, ’ chain has been 
thought to modulates the activity of FXIII and FII, alter clot architecture, and interfere with 
platelet fibrinogen interaction. The association of rFII and FXIII with ’FI indicates that the 
later may influence the structure and properties of fibrin clots. For instance, it has been suggested 
that ’ concentrate and speed up the rate of FXIII activation leading to extensive crosslinking of 
fibrin monomers. This alters the stability of fibrin clot developed in vitro by increasing clot’s 
ability to resist lysis by plasmin and other proteases.   
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Chapter 5 Characterizing the cell adhesion properties of the native ’pdFI-
pdFN complex 
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Abstract  
 
In this section, the biological activity of the isolated complex was tested with an in vitro 
cell adhesion assay. Human Foreskin Fibroblasts and Human Umbilical Vein Endothelial cells 
(HUVEC) were tested for their abilities to adhere to fibrin clots made from unfractionated pdFI, 
the purified ’pdFI-pdFN complex, and an equimolar mixture of pdFI and pdFN. Results 
showed that the rate and number of cells attaching was diminished in the absence of FN. 
Relatively few cells attached to fibrin matrix made from pdFI. Cell attachment was only 
modestly greater in fibrin made from the same FI but with FN added to a stoichiometric level 
with respect to the total FI initially present. Conversely, an increased amount of cells were 
adhered to clots made from the native complex. The greatly increased efficiency of fibroblast 
and HUVEC attachment to fibrin made from γγ’pdFI-pdFN complex indicates a more efficient 
presentation of FN relative to that of fibrin made from an equivalent amount of FI an FN, but 
having a more random presentation due to a predominance of F1. The nature by which FN is 
presented within fibrin clots to facilitate the initiation of wound healing is not well detailed.   
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Introduction  
 
FN within ECM provides substrates that facilitate cell adhesion and migration during 
development, wound healing, and other processes. FN also participates in other cellular functions 
including proliferation, survival, and differentiation. Following vascular injury, the blood 
clotting system is activated leading to the formation of a clot that seal the injured site and stop 
bleeding. In addition to restoring the integrity of the vascular system, the clot also serves as 
provisional matrix for cell adhesion and migration into the wounded tissue to initiate the healing 
process. These functions are mediated by the clot’s main protein components, fibrin with ~94.9% 
and fibronectin with ~4.4% of the total mass of the clot [1]. FN covalently cross-linked to fibrin 
clot by FXIIIa plays critical roles in the subsequent remodeling and cellular responses. It forms 
stable matrix at the wounded area to which different cell types and ECM components can attach 
and spread. This process is enabled when FN incorporated into fibrin-FN complex adopts an 
extended conformation within the complex which results in exposure of cryptic cell binding 
domains to facilitate cellular processes [2]. Bound FN also plays important roles in tissue 
debridement, wound repair, and augmenting the binding of fibrin clot to macrophages for 
subsequent phagocytosis [3]. 
  Numerous studies have demonstrated the ability of FN to mediate the attachment of 
various cell types [4]. For instance, studies investigating the migration of macrophages in three-
dimensional fibrin clot revealed that both FXIII and FN exhibited inhibitory effect on 
macrophage spreading on fibrin surface [5]. FN cross-linked to fibrin polymer inhibits 
macrophage migration by linking cells to the fibrin clot [5]. The linking occurs between R on 
macrophage surface and specific domain of FN containing the RGDS sequence [6-10]. The 
migration inhibitory effect of FN was reversed by adding an excess of a synthetic peptide 
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containing the RGDS FN cell binding sequence to the fibrin gel. The synthetic peptide saturated 
binding sites on cross-linked FN and greatly enhanced macrophage migration. Other studies have 
shown that cells did not migrate into clots formed from FN-depleted plasma. Cells migration was 
reversed by the addition of FN to plasma prior to clotting indicating that FN has to be 
incorporated by FXIIIa [11]. 
FN covalently cross-linked to fibrin clot promotes hemostasis and stabilize the clot by 
binding to collagen and glycosaminoglycans. Corbett have shown that the covalent crosslinking 
of FN to fibrin is needed for optimal adhesion of the clot to cellular and ECM [12] specifically 
collagen. Separate studies found that the adherence of clot to collagen is largely dependent on the 
concentration of FN component of the fibrin sealant [13]. FN covalently incorporated into fibrin 
clot is also critical in enhancing the binding of fibrin to macrophages for subsequent 
phagocytosis. 
 FN incorporated into fibrin clots by FXIII significantly improves clot retraction by 
nucleated cells expressing the integrin α5β1, suggesting that FN influence the process of tissue 
remodeling. The extent of retraction was shown to depend on the RGD, synergy sites in FN, and 
the covalent incorporation of FN into the fibrin matrix. During clot formation, fibronectin assist 
in removing soluble fibrin that leaves the area of clotting. Furthermore, the inclusion of FN in 
fibrin clot may play role in macrophage clearance of fibrin from circulation following trauma or 
inflammation.  
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Materials and Methods 
 
Materials 
 
All chemicals of highest purity were purchased from Sigma Chemical Company (St. 
Louis, MO). Materials for cell culture were purchased from Lonza (Walkersville, MD). The 
native complex, fibrinogen, and fibronectin were purified from pool of human plasma donated 
by the U.S. Army Materials Command (Fort Detrick, MD) as described previously. Recombinant 
FXIII, expressed in Pichia Pastoris, was purified on His-Bind Resin. Recombinant thrombin was 
bought from The Medicines Company (Parsippany, NJ). Human foreskin fibroblasts and 
HUVEC cells were kindly provided by Dr. Mark A. Carlson (University of Nebraska Medical 
Center). 
Cell culture 
 
All procedures were performed under sterile condition in NUAIRE Biological Safety 
Cabinets. Human foreskin fibroblasts and HUVEC were cultured in 75 cm
2
 flasks coated with 2 
μg/ml pdFN.  Cells were grown at 37 °C in a humidified 5% Co2 in DMEM supplemented with 
20% FBS, 20 ng/ml FGF1, 19 U/ml heparin, 2 mM L-glutamine, 100 U/ml penicillin, and 100 
μg/ml streptomycin. After cells were grown to confluence, culture media was removed and cells 
were rinsed with PBS buffer then harvested by addition of 2 ml of 1x trypsin in PBS buffer. 
Flasks were incubated in CO2 incubator and gently pipetted until cells were visibly released from 
the flask’s surface. Trypsin was inactivated by the addition of 30 ml of growth media. Cell 
suspension was transferred to 50 ml conical tube and cells were pelleted by centrifugation at 600 
xg for 5 minutes. Supernatant was removed and cells pellet were re-suspended in 50 ml growth 
medium. To determine the number of cells, cells were mixed with Trypan Blue Stain (Gibco by 
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life Technologies), transferred to dual chamber counting slides and counted using TC20 
automated cell counter (Bio-Rad). 
Preparation of coated plate wells 
 
Cell attachment properties of the different fibrin clots preparations were examined using 
96 and 24 well plates.  Clots were formed at 2 mg/ml of fibrinogen concentration. Isolated 
’pdFI-pdFN complex, pdFI, and an equimolar mixture of pdFI and pdFN were added to the 
designated wells. Appropriate amounts of rFXIIIa, CaCl2 solution, and ringer’s solution were 
added followed by rFIIa to trigger clot formation. Plates were incubated on a rotating mixer at 
room temperature for 2 hours to allow the formation of maximum cross-linked clots. Un-treated 
wells served as control.  
Cell adhesion assays 
 
Before seeding, plates were exposed to UV lights for 30 min to eliminate any potential 
pathogens. HUVEC were seeded in DMEM at 47,800 cells per well whereas human foreskin 
fibroblasts were seeded at 4,000 cells per well. Cells were allowed to attach for either 30 min, 1 
hour, or 3 hours at 37 °C in a humidified 5% Co2 environment. Wells were washed 3 times with 
PBS buffer containing calcium and magnesium, and cells were fixed for 15 min by adding 3.7% 
formaldehyde in PBS buffer. Formaldehyde solution was removed and wells were washed 3 
times with PBS buffer containing calcium and magnesium. Fixed cells were stained with 300 nM 
diamidino-2-phenylindole (DAPI) (Thermo Fisher Scientific) in PBS for 5 minutes. DAPI was 
removed and wells were washed with PBS buffer. Attached cells were visualized with EVOS 
fluorescent Microscope (Advanced Microscopy Group, Life Technologies) using a 10X 
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objective. Plates were kept wrapped with aluminum foil during the staining and visualization 
process.  
Statistical analysis 
 
The number of cells adhering to the various types of wells was quantified with ImageJ 
software (The National Institute of Health). All data are expressed as means and standard 
deviations. Differences in the number of adhered cells were analyzed by one-way Analysis of 
variance (ANOVA) using the software GraphPad Prims, version 5.0 (GraphPad Software, San 
Diego, CA). P values lower than 0.05 were considered to indicate statistical significance. 
Results  
 
Human fibroblasts and human umbilical vein endothelial cells are examples of cell types 
which are stimulated by fibronectin at wound surfaces. Human fibroblasts and HUVEC adhesion 
to fibrin matrices made from the isolated γγ’pdFI-pdFN complex was examined with an in vitro 
adhesion model and compared to adhesion to fibrin made from pdFI or an equimolar mixture of 
pdFI and pdFN. Clots formed from γγ’pdFI-pdFN complex isolated from human plasma 
contained an equal amount of FN and γγ’FI. Human fibrinogen used consist of the typical levels 
of 8 to 15% ’FI, 90% homodimeric FI, as typically found in human plasma. rFXIIIa 
covalently cross-linked FN to the α-chain of fibrin to form high molecular weight heterodimers 
and polymers. 
Cells were harvested with trypsin digest and therefore devoid of cell-surface fibronectin 
[14]. This ensures that cells will not utilize their own FN to facilitate adhesion. The number of 
cells adhering was quantified and the results obtained are shown in Figures 5.1 through 5.4. As 
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expected cell attachment was markedly decreased in the absence of FN. After 3 hours of 
incubation, few cells were attached to untreated wells and wells containing clots made from 
plasma FI. This corroborates previous observations that FN is essential in augmenting the 
adhesion and spreading of various types of cells [15-18]. Additional cell adhesion experiments 
were conducted to determine whether the covalent incorporation of FN into fibrin clot by FXIII 
can improve cell adhesion. These set of experiments were also designed to reveal whether the 
biological activity of the native complex could be replicated with an equimolar mixture of 
exogenous FI and FN. The covalent incorporation of FN into fibrin clots resulted in a marked 
increase in cell attachment. The adhesion of HUVECs cells was increased by a factor of 1.6 and 
fibroblasts by a factor of 8.5. This agrees with the previous observations that FN covalently 
bound to fibrinogen or fibrin substrata by FXIII greatly enhanced the ability of the substrata to 
support cell adhesion [19]. FN covalently bound to substrata was thought to result in an 
orientation of FN molecules more favorable for cell interactions than the orientation that would 
occurs with noncovalently bound FN.  
Both HUVEC and fibroblasts cells demonstrated an increase in the rate and number of 
cells attached when the native complex was present. The adhesion of both types of cells was 
significantly increased on clots made from the native complex. The attachment of HUVEC cells 
was increased by a factor of 2.5 and fibroblasts by a factor of 2.6 than the attachment observed 
on clots from a mixture of pdFI and pdFN. These results show that despite the presence of an 
equal amount of FN on the native complex and a mixture of FI and FN, the orientation of FN in 
the native complex is more favorable for cell adhesion. The covalent of incorporation of 
exogenous FN into fibrin clots could not duplicate the cell adhesion properties of the isolated 
complex.  The rates of attachment of HUVECs and fibroblasts cells to the different types of clots 
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are shown in Figures 5.5 and 5.6. Rates of cells attachment to clots made from the native 
complex were faster compared to clots from pdFI and a mixture of pdFI and pdFN. 
 
Figure 5.1 Fibroblasts adhesion to A) propylene; B) fibrin clots formed from plasma pdFI; 
C) fibrin clots formed from equimolar concentration of pdFI and pdFN; D) fibrin clots 
formed from the isolated ’pdFI-pdFN complex.  Cells were allowed to adhere for 3 hour 
then visualized using EVOS fluorescent Microscope 
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Figure 5.2 HUVECs adhesion to: A) propylene; B) fibrin clots formed from pdFI; C) fibrin 
clots formed from equimolar concentration of pdFI and pdFN; D) fibrin clots formed from 
’pdFI-pdFN complex.  Cells were allowed to adhere for 3 hours then visualized on EVOS 
fluorescent Microscope. 
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Figure 5.3 Quantitation of fibroblasts cells attachment.  Equal numbers of cells were seeded 
onto wells containing clots derived from FI, native complex, and a mixture of pdFI and pdFN. 
Cells were allowed to attach for 3 hours and the extent of cell adhesion was quantitated with 
ImageJ. 
 
 
Figure 5.4 Quantitation of HUVEC cells attachment.  Equal numbers of cells were seeded 
onto wells containing clots derived from FI, native complex, and a mixture of pdFI and pdFN. 
Cells were allowed to attach for 3 hours and the extent of cell adhesion was quantitated with 
ImageJ. 
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Figure 5.5 Time course of fibroblasts cells adhesion.  Cells were allowed to attach for 30 min, 
1 h, and 3 h at 37 then visualized with EVOS fluorescent Microscope. The number of cells 
attached was calculated from three independent experiments. Cells were quantified with ImageJ.  
 
 
 
Figure 5.6 Time course of HUVECs cells adhesion.  Cells were allowed to attach for 30 min, 1 
h, and 3 h then visualized with EVOS fluorescent Microscope. The number of cells attached was 
calculated from three independent experiments. Cells were quantified with ImageJ.  
 
0
20
40
60
80
100
120
140
160
0 50 100 150 200
Propylene
Clots from FI
Clots from a mixture of FI and FN
Clots from FI-FN Complex
0
200
400
600
800
1000
1200
0 50 100 150 200
Propylene
Clots from FI
Clots from a mixture of FI and FN
Clots from FI-FN Complex
117 
 
Discussion  
 
Cell culture studies were performed to assess whether and to what extent the isolated 
’pdFI-pdFN complex affect cell adhesion. Our studies showed that fibrin matrices derived 
from ’pdFI-pdFN complex induced greater human fibroblasts and HUVEC attachment than 
fibrin matrices made from an equimolar mixture of pdFI and pdFN or pdFI alone. Unlike an 
exogenous mixture of FI and FN coated on surface, the ’pdFI-pdFN complex provides a more 
accurate substrate that resembles the provisional matrix found during wound healing. More cells 
were adhered to clots developed from an equimolar mixture of FI and FN than clots from FI. 
This agrees with the finding of Corbett at el that FXIIIa mediated covalent crosslinking of FN to 
fibrin clot is required for maximal cell adhesion. Cells attachment and spreading was maximal on 
FN-fibrin clots but significantly decreased on non-crosslinked clots.   
It’s well known that soluble FN is a poor substrate for many cell types; however, the cell 
binding avidity of FN is enhanced upon deposition on surfaces. Immobilization is thought to 
cause FN to undergo an irreversible conformational change to the more extended form that 
exposes cell binding sites previously hidden in the molecule. Under physiological pH and salt 
concentration, soluble FN assumes a compact structure stabilized by hydrophobic interactions 
between acidic and basic residues. In contrast, SEM studies revealed that immobilized pdFN 
exists as elongated thread-like particles with greater separation between the two N-termini of the 
dimer. This reversible change in pdFN conformation is thought to expose several cryptic binding 
sites that promote the interactions of cells with fibronectin. It is possible that interaction of FN 
with ’FI causes a conformational change of FN that is different than the interaction of FN with 
FI that contains ~ 10% ’ and 85%  FI subspecies. We have shown, using methods that 
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include gel filtration, analytical ultracentrifugation, and dynamic light scattering that FN interact 
more tightly with ’FI than FI. Perhaps cells binding sites in FN covalently cross-linked to 
’FI are more ordered compared to binding sites on FN bound to FI. The covalent binding of FN 
to ’FI may also exposes additional cell binding sites that are not accessible in predominately 
pdFI-pdFN matrices. 
Our studies have demonstrated that the ’pdFI-pdFN complex is composed exclusively 
of the ’pdFI species in a 1:1 mixture with pdFN. Assuming that the average concentrations of 
FI and FN in plasma are about 3 mg/ml and 0.3 mg/ml, respectively. Also, assuming that the 
’pdFI variant represent about 10% of total plasma fibrinogen. The concentration of ’pdFI 
then becomes about 0.3 mg/ml. Since FN associate only with ’pdFI species, the molar ratio of 
’FI to FN in plasma becomes 1:1. Several in vitro experiments indicate that the maximum cell 
adhesion and migration occurred at the physiologic 1:10 mass ratio of FI to FN. For example, 
Greiling et al reported that fibroblast migration into a fibrin clot was dependent on FN and that 
the optimal migration occurred at a ratio of 10:1 of FI:FN. In addition, Siobhan and colleagues 
reported that cell spreading and cytoskeletal organization are induced by adhesion to a three 
dimensional FN-fibrin matrix made from the physiologic 10:1 mass ratio of pdFI to pdFN [20]. 
Consequently, the FN-fibrin matrices used in these in vitro experiments correspond to the ’FI-
FN complex.  
Studies examining the distribution of FN on peripheral blood cells provided useful 
insights on how FN might function in in vivo. Grinnell and Feld found that FN was distributed 
along fibrin strands of blood clots from normal health adult donors. They concluded that blood 
clots formed in vivo are likely a fibrin-fibronectin complex and the presence of continuous layer 
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of FN on the clots may serve to provide mechanical stability that necessary for clot retraction 
[21]. Large amount of FN is covalently incorporated into fibrin clots formed in vivo during 
clotting [8]. Studies examining the distribution of FN during wound healing have shown that FN 
was part of the fibrin clot and distributed along fibrin strands [22]. Bound FN forms the 
substratum for subsequent cell migration and attachment to the clot. FN also mediates fibrin 
crosslinking and stabilization at the wound surfaces. 
Together with the work of Bar et al [13] who showed that fibronectin was necessary for 
fibrin sealants binding to collagen surfaces, these studies indicate that the combination of cryo 
precipitation, ammonium sulfate fractionation and DEAE chromatography can be used to 
produce a fibrin sealant with increased clot strength, improved solubility, enhanced collagen 
binding and increased cell attachment for use in hemostasis and wound repair.  
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Chapter 6 Interaction of FN with FI by ligand blotting 
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Abstract  
 
We employed ligand blotting to study the interaction of fibronectin with fibrinogen at 
room temperature. Results showed that FN bound to unfractionated FI, isolated complex,  and 
’ FI subspecies.  Both α- and β-chains of fibrinogen exhibited strong signal indicating that 
fibronectin binding sites are localized in these two chains. The binding of FN to the α-chain of FI 
is in agreement with the previous observations. However, FN binding to the β-chain of FI is a 
novel finding. Additional experiments were carried out to test whether FN binding to 
immobilized FI can be inhibited by the addition of FN. Results indicated that FI in solution 
competed with immobilized FI for FN binding. This corroborates the DLS results that FN 
interacts with FI in solution.  
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Materials and Methods  
 
Materials 
 
All reagents of highest purity were purchased from Sigma Chemical Company (St. Louis, MO) 
unless otherwise noted. Human plasma was donated by the U.S. Army Materials Command (Fort 
Detrick, MD). Human plasma fibrinogen depleted of fibronectin, plasminogen, and von 
Willebrand Factor was purchased from Enzyme Research Laboratories (South Bend, IN). Human 
fibrinogen was purified from plasma by cryoprecipitation followed by two ethanol precipitation 
as previously described [1]. Human fibronectin was isolated from plasma on Gelatin Sepharose 
as previously described [2]. Plasma fibrinogen  variant with intact and degraded α-chains were 
obtained from ammonium sulfate precipitated fibrinogen fractionation on DEAE Sepharose as 
previously described. Plasma fibrinogen ’ variant with intact and degraded α-chains were 
obtained from the disruption of the native ’pdFI-pdFN complex on gelatin Sepharose as 
described before.  
Ligand blotting assay 
 
Fibrinogen containing species were analyzed under reducing condition on 4-12% 
NuPAGE Bis-Tris Mini Gels (Life Technologies) as previously described. Gels were 
electroblotted onto polyvinylide fluoride (PVDF) membranes (Millipore, Billerica, MA) for 45 
min at 25 volts. Blots were blocked in 50 ml of 5% casein in TBST (Tris-buffered Tween-20) for 
30 minutes at room temperature. Blots were used in the following analysis. 
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Binding of FN to immobilized FI 
 
To test whether FN interact with the various FI species, blots were incubated with 200 
nm FN in TBST buffer for one hour at room temperature. To remove unbound material, blots 
were washed three times with TBST buffer then incubated with an anti-plasma fibronectin 
monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for 30 min at room 
temperature. Blots were washed three times with TBST then incubated with an anti-mouse IgG 
peroxidase conjugate (Sigma Aldrich) then developed with DAB/Metal concentrate and stable 
peroxide substrate buffer (Thermo Scientific, Rockford, IL). 
Competitive inhibition of FN binding to immobilized FI  
 
Blots were incubated with a mixture of plasma FN and ’FI for one hour at room 
temperature. FN (200 nm) was added with an increasing concentrations of ’FI. Blots were 
washed with TBST, incubated with an anti-plasma fibronectin monoclonal antibody, detected 
with an anti-mouse IgG peroxidase conjugate, and then visualized with DAB/Metal concentrate 
and stable peroxide substrate buffer.  
Results  
 
The interaction of fibronectin with fibrinogen species was investigated with ligand 
blotting assay. Unfractionated pdFI, the isolated ’pdFI-pdFN complex,  and ’ FI subspecies 
with intact and degraded α-chains were analyzed under denaturing condition on 4-12%. Reduced 
gels were electrophoretically transferred to PVDF membrane and propped with different 
antibodies. Anti-FN blot (Figure 6.2) shows that the unfractionated FN-depleted pdFI (Enzyme 
Research),  and ’ FI subspecies contain some level of FN. Anti-’pdFI is shown in Figure 
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6.3. The unfractionated pdFI (lane 2) exhibits some level of FN consistent with the reported ~ 10 
to 15% ’ and ~ 85% . As expected, the pdFI species (lanes 5 and 6) are devoid of ’ 
whereas the isolated complex (lane 4) and ’pdFI species (lanes 7 and 8) display significant 
amount of ’-chain.  
Interaction between FI and FN 
 
To investigate whether fibrinogen interact with fibronectin, blots were incubated with FN 
then detected with an anti-FN. Results are displayed in Figure 6.2. Panel shows the reduced gel 
analysis of the FI and FN samples. The α-chain of the isolated complex (lane 4) is severely 
degraded. Lanes 5 and 6 shows the severely degraded and intact α-chain ’pdFI, respectively. 
Lanes 7 and 8 display the intact and completely degraded ’pdFI, respectively. Panel B displays 
the ligand blot. It’s clear from the figure that FN interacts with FN at room temperature. Both α- 
and β-chains of FI exhibited strong signal indicating that FN binding sites in FI are located in 
these chains. FN was able to bind to ’pdFI with completely degraded α-chain (lane 8) 
providing further evidence that FN interact with β-chain independent of the α-chain. The absence 
of signal corresponding to the  and ’ suggest that FN does not interact with both chains.  
Competition experiments 
 
Additional experiments were conducted to determine whether FI in solution could 
interact with FN. The binding of FN to immobilized FI was competitively inhibited with by the 
addition of ’pdFI. Blots were treated with a mixture of ’pdFI and FN in which an increasing 
amount of ’pdFI was added to a constant level of FN.  Results are shown in Figure 6.4. It is 
clear from the blots that the intensity of the signal decreased as more ’pdFI was added to FN. 
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This shows that the amount of FN available to bind to FI individual chains immobilized on the 
blot was decreased as more ’pdFI was added to the mixture. This demonstrates that ’pdFI in 
solution interacts with FN. The lower intensity of the β-chain compared to the α-chain suggests 
that the β-chain has low affinity for FN. FI in solution and FI immobilized on blot compete for 
binding to FN. 
Figure 6.1 Anti-fibronectin (A) and anti-fibrinogen ’-chain (B) Western blot analysis of 
fibrinogen.  Samples (6 µg) were analyzed under reducing condition in 4-12% SDS-PAGE then 
transferred to PVDF membrane. Lane 1: molecular weight marker; Lane 2: pdFI (ER); Lane 3: 
pdFN; Lane 4: ’pdFI-pdFN; Lane 5: pdFI des α-chain; Lane 6: pdFI; Lane 7: ’pdFI; Lane 
8: ’pdFI des α-chain. 
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Figure 6.2 Gel electrophoresis (A) and ligand blotting analysis (B) of fibrinogen.  Samples (6 
µg) were analyzed under reducing condition in 4-12% SDS-PAGE and stained with colloidal 
blue or transferred to PVDF membrane. Blot was incubated with pdFN then an anti-plasma 
fibronectin monoclonal antibody and probed with an anti-mouse IgG peroxidase conjugate. Lane 
1: molecular weight marker; Lane 2: pdFI (ER); Lane 3: pdFN; Lane 4: ’pdFI-pdFN; Lane 5: 
pdFI des α-chain; Lane 6: pdFI; Lane 7: ’pdFI; Lane 8: ’pdFI des α-chain. 
 
 
 
Figure 6.3 Ligand blot analysis of fibronectin binding to immobilized fibrinogen and 
fibrinogen in solution.  Samples (3 µg) were analyzed under reducing condition in 4-12% SDS-
PAGE then transferred to PVDF membrane. Blots were incubated with mixtures of pdFN and 
’pdFI. (A) 1:0, (B) 1:20, (C) 1:30. Blots were incubated with an anti-plasma fibronectin 
monoclonal antibody and probed with an anti-mouse IgG peroxidase conjugate. Lane 1: 
molecular weight marker; Lane 2: pdFI; Lane 3: ’pdFI; Lane 4: ’pdFI des α-chain. 
A B 
A B C D 
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Discussion 
 
Ligand blotting experiments revealed that FN bound to FI containing species that include 
unfractionated pdFI, pdFI, ’pdFI, and the isolated complex. The binding of FN to FI 
occurred whether FI in solution or immobilized on blot. This contradicts earlier observations that 
demonstrated FN interact only with fibrin.  For example, Makogonenko reported that fibronectin 
did not bind to immobilized fibrinogen but bound fibrin with high affinity [3]. Fibronectin 
binding sites were thought to be cryptic in fibrinogen but become exposed when fibrinogen is 
converted to fibrin. Other observations have demonstrated that FN bind to fibrinogen in the cold 
but such binding is abolished upon warming the fibrinogen to 22 °C [4]. Other studies have 
shown that FN bound to fibrinogen-Sepharose at low temperature but not  
The binding sites of FN are located in the α- and β-chains of FI. FN bound to the β-chain 
even in the absence of the α-chain .The α-chain appears to be the higher affinity binding site 
whereas the β-chain is the lower affinity binding site. The binding of FN to the α-chain of FI is in 
agreement with numerous previous studies [5-7]. The presence of additional FN binding sites in 
FI was suggested by others. For example, using electron microscopy, Erickson have suggested 
that fibronectin attachment to fibrinogen involved the g-chain [8]. Other studies have shown that 
FN crosslinked fibrin with degraded α-chains, indicating the presence of secondary crosslinking 
sites in fibrin [7]. Therefore, the binding of fibronectin to fibrinogen is complex and may involve 
several domains. However, no studies have reported the binding of fibronectin to the β-chain of 
fibrinogen. 
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